{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "0f1313ec",
   "metadata": {
    "scrolled": false
   },
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import re\n",
    "\n",
    "# path = \"/Users/marcosmaldacena/Downloads/Thesis Data/2006_2025_2-19_v8.csv\"\n",
    "path = (\"/Users/marcosmaldacena/Downloads/Thesis Data/2016_2020_Cap_Goods_2-20_v9.csv\")\n",
    "df = pd.read_csv(path)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "1f9f672b",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.columns\n",
    "import ast\n",
    "\n",
    "# Convert the whole column safely\n",
    "# df['tariff_questions_bow'] = df['tariff_questions_bow'].apply(ast.literal_eval)\n",
    "# df['tariff_questions'] = df['tariff_questions'].apply(ast.literal_eval)\n",
    "df['questions'] = df['questions'].apply(ast.literal_eval)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "id": "052080b1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1000x800 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "categories = ['Classified Only By B-o-W', 'Classified Only By LLM', 'Classified By Both', 'Classified By Neither']\n",
    "counts = [total_only_bow, total_only_tariff, total_both, total_neither]\n",
    "\n",
    "# Create two subplots with a broken y-axis\n",
    "fig, (ax1, ax2) = plt.subplots(\n",
    "    2, 1, \n",
    "    sharex=True, \n",
    "    figsize=(10, 8), \n",
    "    gridspec_kw={'height_ratios': [1, 3]}\n",
    ")\n",
    "\n",
    "# Set colors manually for each bar\n",
    "bar_colors = ['C0', 'C1', 'C2', 'C3']\n",
    "\n",
    "# Top plot (zoomed out to show the big bar)\n",
    "ax1.bar(categories, counts, color=bar_colors)\n",
    "ax1.set_ylim(max(counts) - 400, max(counts) + 100)\n",
    "\n",
    "# Bottom plot (zoomed in to show small bars)\n",
    "ax2.bar(categories, counts, color=bar_colors)\n",
    "ax2.set_ylim(0, 300)\n",
    "\n",
    "# Hide the spines between ax1 and ax2\n",
    "ax1.spines['bottom'].set_visible(False)\n",
    "ax2.spines['top'].set_visible(False)\n",
    "ax1.tick_params(labeltop=False)  # don't put tick labels at the top\n",
    "\n",
    "# Add diagonal lines at the break\n",
    "d = .5  # size of diagonal lines\n",
    "kwargs = dict(marker=[(-1, -d), (1, d)], markersize=12, linestyle='none', color='k', mec='k', mew=1, clip_on=False)\n",
    "ax1.plot([0, 1], [0, 0], transform=ax1.transAxes, **kwargs)\n",
    "ax2.plot([0, 1], [1, 1], transform=ax2.transAxes, **kwargs)\n",
    "\n",
    "# Titles and labels\n",
    "fig.suptitle('Comparison of Tarrif-Related Question Classification Methods', fontsize=14, fontweight='bold')\n",
    "ax2.set_ylabel('Number of Questions', fontsize=14, fontweight='bold')\n",
    "\n",
    "plt.xticks(rotation=10)\n",
    "\n",
    "plt.tight_layout()\n",
    "\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "87a19bbb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1000x800 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "def plot_classification_normal(categories, counts, title='Comparison of Questions', ylabel='Number of Questions'):\n",
    "    \"\"\"\n",
    "    Plots a normal bar chart (no broken axis) with different colors for each bar.\n",
    "    \"\"\"\n",
    "\n",
    "    fig, ax = plt.subplots(figsize=(10, 8))\n",
    "\n",
    "    # Set colors manually for each bar\n",
    "    bar_colors = ['C0', 'C1', 'C2', 'C3']\n",
    "\n",
    "    ax.bar(categories, counts, color=bar_colors)\n",
    "\n",
    "    # Titles and labels\n",
    "    ax.set_title(title, fontsize=14, fontweight='bold')\n",
    "    ax.set_ylabel(ylabel, fontsize=14, fontweight='bold')\n",
    "\n",
    "    # Rotate x-axis labels\n",
    "    plt.xticks(rotation=10)\n",
    "\n",
    "    plt.tight_layout()\n",
    "\n",
    "    plt.show()\n",
    "\n",
    "    \n",
    "categories = ['Classified Only By B-o-W', 'Classified Only By LLM', 'Classified By Both', 'Classified By Neither']\n",
    "counts = [9, 2, 14, 200]\n",
    "\n",
    "plot_classification_normal(\n",
    "    categories, counts,\n",
    "    title='Comparison of Inflation-Related Question Classification Methods',\n",
    "    ylabel='Number of Unique Questions'\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "a63bd9e9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1000x800 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# import matplotlib.pyplot as plt\n",
    "\n",
    "# categories = ['Classified Only By B-o-W', 'Classified Only By LLM', 'Classified By Both', 'Classified By Neither']\n",
    "# counts = [total_only_bow, total_only_tariff, total_both, total_neither]\n",
    "\n",
    "# # Create two subplots with a broken y-axis\n",
    "# fig, (ax1, ax2) = plt.subplots(\n",
    "#     2, 1, \n",
    "#     sharex=True, \n",
    "#     figsize=(10, 8), \n",
    "#     gridspec_kw={'height_ratios': [1, 3]}\n",
    "# )\n",
    "\n",
    "# # Use default matplotlib colors\n",
    "# colors = plt.rcParams['axes.prop_cycle'].by_key()['color']\n",
    "\n",
    "# # Top plot (zoomed out)\n",
    "# ax1.bar(categories, counts, color=colors)\n",
    "# ax1.set_ylim(max(counts) - 400, max(counts) + 100)\n",
    "\n",
    "# # Bottom plot (zoomed in)\n",
    "# ax2.bar(categories, counts, color=colors)\n",
    "# ax2.set_ylim(0, 300)\n",
    "\n",
    "# # Hide spines between plots\n",
    "# ax1.spines['bottom'].set_visible(False)\n",
    "# ax2.spines['top'].set_visible(False)\n",
    "\n",
    "# # Remove ticks and labels from top plot\n",
    "# ax1.tick_params(labeltop=False, bottom=False)\n",
    "# ax1.set_xticklabels([])\n",
    "\n",
    "# # Bottom plot keeps x-ticks\n",
    "# ax2.tick_params(labelbottom=True)\n",
    "\n",
    "# # Add diagonal break lines\n",
    "# d = .5\n",
    "# kwargs = dict(marker=[(-1, -d), (1, d)], markersize=12, linestyle='none', color='k', mec='k', mew=1, clip_on=False)\n",
    "# ax1.plot([0, 1], [0, 0], transform=ax1.transAxes, **kwargs)\n",
    "# ax2.plot([0, 1], [1, 1], transform=ax2.transAxes, **kwargs)\n",
    "\n",
    "# # Titles and labels\n",
    "# fig.suptitle('Comparison of Questions', fontsize=16, fontweight='bold')\n",
    "# ax2.set_ylabel('Number of Questions', fontsize=14, fontweight='bold')\n",
    "\n",
    "# # Rotate x-axis labels slightly\n",
    "# plt.xticks(rotation=10)\n",
    "\n",
    "# # Fit layout nicely\n",
    "# plt.tight_layout()\n",
    "\n",
    "# plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "63f3e956",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "258\n"
     ]
    }
   ],
   "source": [
    "total_questions_bow = df['tariff_questions_bow'].apply(len).sum()\n",
    "print(total_questions_bow)\n",
    "# print(df['tariff_questions_bow'].iloc[1])\n",
    "# print(type(df['tariff_questions_bow'].iloc[0]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "c1520db4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "270\n"
     ]
    }
   ],
   "source": [
    "total_questions_bow = df['tariff_questions'].apply(len).sum()\n",
    "print(total_questions_bow)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "7f45a5ea",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'[\"I can picture Darius in the same jet just doing something different on his iPad. So just a question on tax, can you maybe just talk about what the dynamics are around, how if repatriation come through border adjustments, just give us some color on your kind of net export position, if the Brady bill does goes through I\\'m sure you guys have done some analysis, what should we expect?\", \"I guess, my first question, in listening to Darius, it was interesting to hear that there\\'s some thought, as things kind of shake out, that you guys could benefit once policies are set. Clearly, you\\'re in an export position, but I guess, Im wondering Dave or Darius, how concerned are you guys about trade wars? Clearly, China\\'s been a big growth engine for you. And then also secondly, there\\'s been a lot of tweets around defense pricing, having to come down. And so what -- how do you guys feel, your position there as well? Ann then also secondly, theres been a lot of suites around defense pricing having to come down and how do you guys feel your position there as well?\"]'"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['tariff_questions'][0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "bc0ac676",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b55811f5",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "caa78b67",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4c10a999",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "ac2784fa",
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_names(text):\n",
    "    # Define regex patterns for executives and analysts\n",
    "    executive_section = re.search(r\"Executives:(.*?)Analysts:\", transcript2, re.DOTALL).group(1)\n",
    "    analysts_section = re.search(r\"Analysts:(.*?)Operator:\", transcript2, re.DOTALL).group(1)\n",
    "    return executive_section, analysts_section\n",
    "\n",
    "def extract_presentation(transcript):\n",
    "    # Split the transcript into words to track word positions\n",
    "    words = transcript.split()\n",
    "    \n",
    "    # Find all occurrences of \"Operator:\"\n",
    "    operator_positions = [match.start() for match in re.finditer(r\"Operator:\", transcript)]\n",
    "    \n",
    "    # Check if the operator is mentioned after the first 400 words\n",
    "    if operator_positions and len(\" \".join(words[:400])) < operator_positions[0]:\n",
    "        # Everything before the first mention of \"Operator:\" is the presentation\n",
    "        return transcript[:operator_positions[0]]\n",
    "    \n",
    "    # If there are fewer than two mentions of \"Operator:\", return None\n",
    "    if len(operator_positions) < 2:\n",
    "        return None  # Not enough mentions of \"Operator:\"\n",
    "    \n",
    "    # Check if the gap between the first and second occurrence is less than 100 words\n",
    "    first_gap_word_count = len(transcript[operator_positions[0]:operator_positions[1]].split())\n",
    "    if first_gap_word_count < 100 and len(operator_positions) > 2:\n",
    "        # Use the gap between the first and third mentions\n",
    "        return transcript[operator_positions[0]:operator_positions[2]]\n",
    "    \n",
    "    # Default case: Use the gap between the first and second mentions\n",
    "    return transcript[operator_positions[0]:operator_positions[1]]\n",
    "\n",
    "\n",
    "def extract_q_and_a(transcript):\n",
    "    # Find all occurrences of \"Operator:\"\n",
    "    operator_positions = [match.start() for match in re.finditer(r\"Operator:\", transcript)]\n",
    "\n",
    "    # Ensure there are at least two occurrences\n",
    "    if len(operator_positions) < 2:\n",
    "        return None  # Not enough mentions of \"Operator:\"\n",
    "\n",
    "    # Extract everything after the second occurrence\n",
    "    text_after_second_operator = transcript[operator_positions[1]:]\n",
    "    return text_after_second_operator  \n",
    "\n",
    "\n",
    "def remove_operator_lines(transcript):\n",
    "    \"\"\"\n",
    "    Removes all lines that start with 'Operator:' \n",
    "    (assuming each Operator statement is on a single line).\n",
    "    \"\"\"\n",
    "    # ^Operator:   => line begins with 'Operator:'\n",
    "    # .*          => then remove everything else on that line\n",
    "    # (?:\\n|$)    => include the line break or the end of string\n",
    "    cleaned_transcript = re.sub(r\"^Operator:.*(?:\\n|$)\", \"\", transcript, flags=re.MULTILINE)\n",
    "    return cleaned_transcript  \n",
    "\n",
    "def create_qna_pairs(transcript, executives, analysts):\n",
    "    \"\"\"\n",
    "    Returns a list of dictionaries:\n",
    "      [\n",
    "        {\n",
    "          \"question\": \"analyst question text here\",\n",
    "          \"answer\": \"all combined executive responses until next question\"\n",
    "        },\n",
    "        ...\n",
    "      ]\n",
    "    Ignores 'Operator:' lines if you run remove_operator_lines() on the transcript first.\n",
    "    \"\"\"\n",
    "    # Split the transcript by speaker\n",
    "    sections = re.split(r\"(?<!\\w)([A-Z][a-zA-Z\\s.']+):\", transcript)\n",
    "\n",
    "    qna_list = []\n",
    "    current_question = None\n",
    "    current_answers = []    \n",
    "\n",
    "    if len(sections) < 3:\n",
    "        return qna_list  # No valid speaker-dialogue chunks\n",
    "\n",
    "    # Walk through the transcript in speaker-dialogue pairs\n",
    "    for i in range(1, len(sections) - 1, 2):\n",
    "        speaker = sections[i].strip()\n",
    "        dialogue = sections[i+1].strip()\n",
    "\n",
    "        # Check if the speaker is an analyst => new question\n",
    "        if any(token in analysts for token in speaker.split()):\n",
    "            # If there's an existing question, finalize its Q&A pair\n",
    "            if current_question is not None:\n",
    "                # Join all answer snippets into one\n",
    "                qna_list.append({\n",
    "                    \"question\": current_question,\n",
    "                    \"answer\": \" \".join(current_answers)\n",
    "                })\n",
    "            \n",
    "            # Start a new question\n",
    "            current_question = dialogue\n",
    "            current_answers = []\n",
    "        \n",
    "        # If the speaker is an executive => part of the answer\n",
    "        elif any(token in executives for token in speaker.split()):\n",
    "            if current_question is not None:\n",
    "                current_answers.append(dialogue)\n",
    "            else:\n",
    "                # There's an executive speaking before any question - optional handling\n",
    "                pass  \n",
    "        else:\n",
    "            # Speaker is neither analyst nor executive (maybe Operator or something else).\n",
    "            # Typically we ignore them unless you want to handle them specially.\n",
    "            pass\n",
    "\n",
    "    # After the loop, if there's a question in progress, finalize it\n",
    "    if current_question is not None:\n",
    "        qna_list.append({\n",
    "            \"question\": current_question,\n",
    "            \"answer\": \" \".join(current_answers)\n",
    "        })\n",
    "\n",
    "    return qna_list  \n",
    "\n",
    "\n",
    "\n",
    "def process_transcript(transcript2):\n",
    "    executives, analysts = extract_names(transcript2)\n",
    "    \n",
    "    # Check if there are no analysts\n",
    "    if not analysts:\n",
    "        # If no analysts, set Q&A to None and presentation to the entire transcript\n",
    "        q_and_a = None\n",
    "        presentation = transcript2\n",
    "        q_and_a_results = None\n",
    "        return q_and_a_results, q_and_a, presentation\n",
    "    \n",
    "    # Extract presentation and Q&A if analysts exist\n",
    "    presentation = extract_presentation(transcript2)\n",
    "    q_and_a = extract_q_and_a(transcript2)\n",
    "    \n",
    "    # Handle cases where Q&A is None\n",
    "    if q_and_a is None:\n",
    "        cleaned_q_and_a = \"\"\n",
    "    else:\n",
    "        cleaned_q_and_a = remove_operator_lines(q_and_a)\n",
    "    \n",
    "    # Create Q&A pairs\n",
    "    q_and_a_results = create_qna_pairs(cleaned_q_and_a, executives, analysts)\n",
    "    \n",
    "    return q_and_a_results, q_and_a, presentation   \n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1e5a31f3",
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fb809790",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "8e16460d",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# Load your DataFrame\n",
    "path = \"/Users/marcosmaldacena/Downloads/Thesis Data/2014_earnings_call_transcripts.csv\"\n",
    "path = \"/scratch/network/mm4846/Thesis Data/transcripts_2006_2025.csv\"\n",
    "\n",
    "\n",
    "def separate(path):\n",
    "\n",
    "    df = pd.read_csv(path)  # Adjust the filename/path as needed\n",
    "\n",
    "\n",
    "    # Add an empty column for presentations\n",
    "    df['presentations'] = None\n",
    "    df['Q&A'] = None\n",
    "\n",
    "    # Process each row\n",
    "    for i in range(len(df)):\n",
    "        try:\n",
    "            # Process the content and assign the result to the 'presentations' column\n",
    "            q_and_a = process_transcript(df.loc[i, 'content'])[1]  \n",
    "            pres = process_transcript(df.loc[i, 'content'])[2]    \n",
    "            df.loc[i, 'Q&A'] = q_and_a          \n",
    "            df.loc[i, 'presentations'] = pres      \n",
    "        except Exception as e:         \n",
    "            # Handle the error (log it, skip the row, etc.)\n",
    "            print(f\"Error processing row {i}: {e}\")    \n",
    "        finally:\n",
    "            # Print progress\n",
    "            print(f\"Processed row {i}\")\n",
    "    return df \n",
    "\n",
    "\n",
    "# df = separate(path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e4d337f6",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "a2e1d549",
   "metadata": {},
   "outputs": [],
   "source": [
    "def find_presentation_range(content, subset):\n",
    "    if not isinstance(content, str) or not isinstance(subset, str):\n",
    "        return (None, None)  # Handle invalid inputs\n",
    "    \n",
    "    content_words = content.split()  # Split content into words\n",
    "    subset_words = subset.split()  # Split the subset into words\n",
    "    \n",
    "    try:\n",
    "        # Locate the start index in `content_words`\n",
    "        for i in range(len(content_words) - len(subset_words) + 1):\n",
    "            if content_words[i:i + len(subset_words)] == subset_words:\n",
    "                start_index = i\n",
    "                end_index = i + len(subset_words) - 1\n",
    "                return (start_index + 1, end_index + 1)  # Return as 1-based indices\n",
    "        return (None, None)  # If not found\n",
    "    except Exception as e:\n",
    "        print(f\"Error: {e}\")\n",
    "        return (None, None)\n",
    "\n",
    "    \n",
    "def add_data(df):\n",
    "# Apply the function to calculate the word range for 'presentations'\n",
    "    df['word_range_pres'] = df.apply(\n",
    "        lambda row: find_presentation_range(row['content'], row['presentations']),\n",
    "        axis=1\n",
    "    )\n",
    "\n",
    "    # Apply the function to calculate the word range for 'Q&A'\n",
    "    df['word_range_q_and_a'] = df.apply(\n",
    "        lambda row: find_presentation_range(row['content'], row['Q&A']),\n",
    "        axis=1\n",
    "    )\n",
    "    df['word_count_pres'] = df['presentations'].apply(lambda x: len(x.split()) if isinstance(x, str) else 0)\n",
    "    df['word_count_q_and_a'] = df['Q&A'].apply(lambda x: len(x.split()) if isinstance(x, str) else 0)\n",
    "\n",
    "    return df\n",
    "\n",
    "df = add_data(df)\n",
    "# Display the DataFrame\n",
    "print(df[['presentations', 'word_count_pres', 'word_count_q_and_a', 'word_range_pres', 'word_range_q_and_a']].head())\n",
    "\n",
    " \n",
    "\n",
    "  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "3d0076c4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ticker</th>\n",
       "      <th>year</th>\n",
       "      <th>quarter</th>\n",
       "      <th>date</th>\n",
       "      <th>content</th>\n",
       "      <th>presentations</th>\n",
       "      <th>Q&amp;A</th>\n",
       "      <th>word_range_pres</th>\n",
       "      <th>word_range_q_and_a</th>\n",
       "      <th>word_count_pres</th>\n",
       "      <th>word_count_q_and_a</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ERIE</td>\n",
       "      <td>2014</td>\n",
       "      <td>1</td>\n",
       "      <td>2014-05-02 16:58:07</td>\n",
       "      <td>Executives:  Scott Beilharz  VP-Capital Manag...</td>\n",
       "      <td>Operator: Good morning and welcome to the Erie...</td>\n",
       "      <td>Operator: Thank you. [Operator Instructions]\\n...</td>\n",
       "      <td>(30, 1698)</td>\n",
       "      <td>(1699, 1882)</td>\n",
       "      <td>1669</td>\n",
       "      <td>184</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>ERIE</td>\n",
       "      <td>2014</td>\n",
       "      <td>3</td>\n",
       "      <td>2014-10-31 12:50:18</td>\n",
       "      <td>Executives: Scott Beilharz - VP, Capital Manag...</td>\n",
       "      <td>Operator:  Good morning and welcome to the Eri...</td>\n",
       "      <td>Operator:  Thank you. (Operator Instructions) ...</td>\n",
       "      <td>(30, 1444)</td>\n",
       "      <td>(1445, 1592)</td>\n",
       "      <td>1415</td>\n",
       "      <td>148</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>489</th>\n",
       "      <td>CHD</td>\n",
       "      <td>2014</td>\n",
       "      <td>4</td>\n",
       "      <td>2015-02-04 03:25:04</td>\n",
       "      <td>Executives: Jim Craigie - Chairman and CEO Mat...</td>\n",
       "      <td>Operator: Good afternoon, ladies and gentlemen...</td>\n",
       "      <td>Operator: Ladies and gentlemen thank you parti...</td>\n",
       "      <td>(23, 17234)</td>\n",
       "      <td>(17235, 17258)</td>\n",
       "      <td>17212</td>\n",
       "      <td>24</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>604</th>\n",
       "      <td>ABBV</td>\n",
       "      <td>2014</td>\n",
       "      <td>2</td>\n",
       "      <td>2014-07-25 11:57:08</td>\n",
       "      <td>Executives:  Larry Peepo  VP, IR Richard Gonz...</td>\n",
       "      <td>Operator: Good morning and thank you for stand...</td>\n",
       "      <td>Operator: Thank you. And this does conclude to...</td>\n",
       "      <td>(19, 2500)</td>\n",
       "      <td>(2501, 2523)</td>\n",
       "      <td>2482</td>\n",
       "      <td>23</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>699</th>\n",
       "      <td>NFLX</td>\n",
       "      <td>2014</td>\n",
       "      <td>1</td>\n",
       "      <td>2014-04-21 20:33:03</td>\n",
       "      <td>Executives: David Wells - Chief Financial Offi...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>700</th>\n",
       "      <td>NFLX</td>\n",
       "      <td>2014</td>\n",
       "      <td>2</td>\n",
       "      <td>2014-07-21 22:10:04</td>\n",
       "      <td>Executives: David Wells - CFO Reed Hastings - ...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>701</th>\n",
       "      <td>NFLX</td>\n",
       "      <td>2014</td>\n",
       "      <td>3</td>\n",
       "      <td>2014-10-15 23:16:11</td>\n",
       "      <td>Executives:  David Wells  Chief Financial Off...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>702</th>\n",
       "      <td>NFLX</td>\n",
       "      <td>2014</td>\n",
       "      <td>4</td>\n",
       "      <td>2015-01-20 20:23:07</td>\n",
       "      <td>Executives: David Wells - CFO Reed Hastings - ...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>747</th>\n",
       "      <td>ES</td>\n",
       "      <td>2014</td>\n",
       "      <td>1</td>\n",
       "      <td>2014-05-02 15:28:06</td>\n",
       "      <td>Executives:  Jeffrey R. Kotkin  Vice Presiden...</td>\n",
       "      <td>Operator: Welcome to the Northeast Utilities E...</td>\n",
       "      <td>Operator:  Thank you. And thank you ladies and...</td>\n",
       "      <td>(118, 8745)</td>\n",
       "      <td>(8746, 8766)</td>\n",
       "      <td>8628</td>\n",
       "      <td>21</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>883</th>\n",
       "      <td>CHRW</td>\n",
       "      <td>2014</td>\n",
       "      <td>1</td>\n",
       "      <td>2014-04-30 14:15:03</td>\n",
       "      <td>Executives: Tim Gagnon - Director of Investor ...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>884</th>\n",
       "      <td>CHRW</td>\n",
       "      <td>2014</td>\n",
       "      <td>2</td>\n",
       "      <td>2014-07-30 12:40:09</td>\n",
       "      <td>Executives: Tim Gagnon - Director of Investor ...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>885</th>\n",
       "      <td>CHRW</td>\n",
       "      <td>2014</td>\n",
       "      <td>3</td>\n",
       "      <td>2014-10-29 22:24:02</td>\n",
       "      <td>Executives:  John Wiehoff  Chief Executive Of...</td>\n",
       "      <td>Operator: Good morning, ladies and gentlemen, ...</td>\n",
       "      <td>Operator: Ladies and gentlemen, thank you for ...</td>\n",
       "      <td>(23, 9613)</td>\n",
       "      <td>(9614, 9627)</td>\n",
       "      <td>9591</td>\n",
       "      <td>14</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>886</th>\n",
       "      <td>CHRW</td>\n",
       "      <td>2014</td>\n",
       "      <td>4</td>\n",
       "      <td>2015-02-04 14:16:08</td>\n",
       "      <td>Executives: Tim Gagnon  Director of Investor ...</td>\n",
       "      <td>Operator: Good morning ladies and gentlemen, a...</td>\n",
       "      <td>Operator: Ladies and gentlemen that does concl...</td>\n",
       "      <td>(25, 9622)</td>\n",
       "      <td>(9623, 9637)</td>\n",
       "      <td>9598</td>\n",
       "      <td>15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1199</th>\n",
       "      <td>BEN</td>\n",
       "      <td>2014</td>\n",
       "      <td>1</td>\n",
       "      <td>2014-01-30 14:01:48</td>\n",
       "      <td>Executives: Gregory Eugene Johnson - Chairman,...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1201</th>\n",
       "      <td>BEN</td>\n",
       "      <td>2014</td>\n",
       "      <td>3</td>\n",
       "      <td>2014-08-03 10:56:06</td>\n",
       "      <td>Executives: Greg Johnson - Chief Executive Off...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1202</th>\n",
       "      <td>BEN</td>\n",
       "      <td>2014</td>\n",
       "      <td>4</td>\n",
       "      <td>2014-10-27 10:57:04</td>\n",
       "      <td>Executives: Greg Johnson - Chief Executive Off...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1478</th>\n",
       "      <td>WMT</td>\n",
       "      <td>2014</td>\n",
       "      <td>1</td>\n",
       "      <td>2013-05-15 00:00:00</td>\n",
       "      <td>Operator: Welcome to the Wal-Mart Earnings Cal...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1479</th>\n",
       "      <td>WMT</td>\n",
       "      <td>2014</td>\n",
       "      <td>2</td>\n",
       "      <td>2013-08-15 08:55:04</td>\n",
       "      <td>Executives: Carol Schumacher  Vice President-...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1480</th>\n",
       "      <td>WMT</td>\n",
       "      <td>2014</td>\n",
       "      <td>3</td>\n",
       "      <td>2013-11-14 10:41:03</td>\n",
       "      <td>Executives: Carol Schumacher - Vice President-...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1481</th>\n",
       "      <td>WMT</td>\n",
       "      <td>2014</td>\n",
       "      <td>4</td>\n",
       "      <td>2014-02-20 09:01:13</td>\n",
       "      <td>Executives: Carol Schumacher  Vice President-...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1482</th>\n",
       "      <td>GWW</td>\n",
       "      <td>2014</td>\n",
       "      <td>1</td>\n",
       "      <td>2014-04-16 11:09:06</td>\n",
       "      <td>Executives: Laura Brown - Senior Vice Presiden...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1483</th>\n",
       "      <td>GWW</td>\n",
       "      <td>2014</td>\n",
       "      <td>2</td>\n",
       "      <td>2014-07-17 13:23:02</td>\n",
       "      <td>Executives: Laura Brown - Senior Vice Presiden...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1484</th>\n",
       "      <td>GWW</td>\n",
       "      <td>2014</td>\n",
       "      <td>3</td>\n",
       "      <td>2014-10-16 00:00:00</td>\n",
       "      <td>Laura Brown: Hello, this is Laura Brown, Senio...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1485</th>\n",
       "      <td>GWW</td>\n",
       "      <td>2014</td>\n",
       "      <td>4</td>\n",
       "      <td>2015-01-26 10:03:03</td>\n",
       "      <td>Executives: Laura Brown - Senior Vice Presiden...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1595</th>\n",
       "      <td>MCD</td>\n",
       "      <td>2014</td>\n",
       "      <td>2</td>\n",
       "      <td>2014-07-22 17:05:06</td>\n",
       "      <td>Executives: Kathy Martin - VP of Investor Rela...</td>\n",
       "      <td>Operator: Hello and welcome to McDonalds July...</td>\n",
       "      <td>Operator: This does conclude todays call and ...</td>\n",
       "      <td>(98, 12988)</td>\n",
       "      <td>(12989, 13001)</td>\n",
       "      <td>12891</td>\n",
       "      <td>13</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1596</th>\n",
       "      <td>MCD</td>\n",
       "      <td>2014</td>\n",
       "      <td>3</td>\n",
       "      <td>2014-10-21 17:10:14</td>\n",
       "      <td>Executives: Chris Stent - VP, IR Don Thompson ...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1597</th>\n",
       "      <td>MCD</td>\n",
       "      <td>2014</td>\n",
       "      <td>4</td>\n",
       "      <td>2015-01-23 17:13:03</td>\n",
       "      <td>Executives: Chris Stent - VP, IR Don Thompson ...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>(None, None)</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     ticker  year  quarter                 date  \\\n",
       "4      ERIE  2014        1  2014-05-02 16:58:07   \n",
       "6      ERIE  2014        3  2014-10-31 12:50:18   \n",
       "489     CHD  2014        4  2015-02-04 03:25:04   \n",
       "604    ABBV  2014        2  2014-07-25 11:57:08   \n",
       "699    NFLX  2014        1  2014-04-21 20:33:03   \n",
       "700    NFLX  2014        2  2014-07-21 22:10:04   \n",
       "701    NFLX  2014        3  2014-10-15 23:16:11   \n",
       "702    NFLX  2014        4  2015-01-20 20:23:07   \n",
       "747      ES  2014        1  2014-05-02 15:28:06   \n",
       "883    CHRW  2014        1  2014-04-30 14:15:03   \n",
       "884    CHRW  2014        2  2014-07-30 12:40:09   \n",
       "885    CHRW  2014        3  2014-10-29 22:24:02   \n",
       "886    CHRW  2014        4  2015-02-04 14:16:08   \n",
       "1199    BEN  2014        1  2014-01-30 14:01:48   \n",
       "1201    BEN  2014        3  2014-08-03 10:56:06   \n",
       "1202    BEN  2014        4  2014-10-27 10:57:04   \n",
       "1478    WMT  2014        1  2013-05-15 00:00:00   \n",
       "1479    WMT  2014        2  2013-08-15 08:55:04   \n",
       "1480    WMT  2014        3  2013-11-14 10:41:03   \n",
       "1481    WMT  2014        4  2014-02-20 09:01:13   \n",
       "1482    GWW  2014        1  2014-04-16 11:09:06   \n",
       "1483    GWW  2014        2  2014-07-17 13:23:02   \n",
       "1484    GWW  2014        3  2014-10-16 00:00:00   \n",
       "1485    GWW  2014        4  2015-01-26 10:03:03   \n",
       "1595    MCD  2014        2  2014-07-22 17:05:06   \n",
       "1596    MCD  2014        3  2014-10-21 17:10:14   \n",
       "1597    MCD  2014        4  2015-01-23 17:13:03   \n",
       "\n",
       "                                                content  \\\n",
       "4     Executives:  Scott Beilharz  VP-Capital Manag...   \n",
       "6     Executives: Scott Beilharz - VP, Capital Manag...   \n",
       "489   Executives: Jim Craigie - Chairman and CEO Mat...   \n",
       "604   Executives:  Larry Peepo  VP, IR Richard Gonz...   \n",
       "699   Executives: David Wells - Chief Financial Offi...   \n",
       "700   Executives: David Wells - CFO Reed Hastings - ...   \n",
       "701   Executives:  David Wells  Chief Financial Off...   \n",
       "702   Executives: David Wells - CFO Reed Hastings - ...   \n",
       "747   Executives:  Jeffrey R. Kotkin  Vice Presiden...   \n",
       "883   Executives: Tim Gagnon - Director of Investor ...   \n",
       "884   Executives: Tim Gagnon - Director of Investor ...   \n",
       "885   Executives:  John Wiehoff  Chief Executive Of...   \n",
       "886   Executives: Tim Gagnon  Director of Investor ...   \n",
       "1199  Executives: Gregory Eugene Johnson - Chairman,...   \n",
       "1201  Executives: Greg Johnson - Chief Executive Off...   \n",
       "1202  Executives: Greg Johnson - Chief Executive Off...   \n",
       "1478  Operator: Welcome to the Wal-Mart Earnings Cal...   \n",
       "1479  Executives: Carol Schumacher  Vice President-...   \n",
       "1480  Executives: Carol Schumacher - Vice President-...   \n",
       "1481  Executives: Carol Schumacher  Vice President-...   \n",
       "1482  Executives: Laura Brown - Senior Vice Presiden...   \n",
       "1483  Executives: Laura Brown - Senior Vice Presiden...   \n",
       "1484  Laura Brown: Hello, this is Laura Brown, Senio...   \n",
       "1485  Executives: Laura Brown - Senior Vice Presiden...   \n",
       "1595  Executives: Kathy Martin - VP of Investor Rela...   \n",
       "1596  Executives: Chris Stent - VP, IR Don Thompson ...   \n",
       "1597  Executives: Chris Stent - VP, IR Don Thompson ...   \n",
       "\n",
       "                                          presentations  \\\n",
       "4     Operator: Good morning and welcome to the Erie...   \n",
       "6     Operator:  Good morning and welcome to the Eri...   \n",
       "489   Operator: Good afternoon, ladies and gentlemen...   \n",
       "604   Operator: Good morning and thank you for stand...   \n",
       "699                                                None   \n",
       "700                                                None   \n",
       "701                                                None   \n",
       "702                                                None   \n",
       "747   Operator: Welcome to the Northeast Utilities E...   \n",
       "883                                                None   \n",
       "884                                                None   \n",
       "885   Operator: Good morning, ladies and gentlemen, ...   \n",
       "886   Operator: Good morning ladies and gentlemen, a...   \n",
       "1199                                               None   \n",
       "1201                                               None   \n",
       "1202                                               None   \n",
       "1478                                               None   \n",
       "1479                                               None   \n",
       "1480                                               None   \n",
       "1481                                               None   \n",
       "1482                                               None   \n",
       "1483                                               None   \n",
       "1484                                               None   \n",
       "1485                                               None   \n",
       "1595  Operator: Hello and welcome to McDonalds July...   \n",
       "1596                                               None   \n",
       "1597                                               None   \n",
       "\n",
       "                                                    Q&A word_range_pres  \\\n",
       "4     Operator: Thank you. [Operator Instructions]\\n...      (30, 1698)   \n",
       "6     Operator:  Thank you. (Operator Instructions) ...      (30, 1444)   \n",
       "489   Operator: Ladies and gentlemen thank you parti...     (23, 17234)   \n",
       "604   Operator: Thank you. And this does conclude to...      (19, 2500)   \n",
       "699                                                None    (None, None)   \n",
       "700                                                None    (None, None)   \n",
       "701                                                None    (None, None)   \n",
       "702                                                None    (None, None)   \n",
       "747   Operator:  Thank you. And thank you ladies and...     (118, 8745)   \n",
       "883                                                None    (None, None)   \n",
       "884                                                None    (None, None)   \n",
       "885   Operator: Ladies and gentlemen, thank you for ...      (23, 9613)   \n",
       "886   Operator: Ladies and gentlemen that does concl...      (25, 9622)   \n",
       "1199                                               None    (None, None)   \n",
       "1201                                               None    (None, None)   \n",
       "1202                                               None    (None, None)   \n",
       "1478                                               None    (None, None)   \n",
       "1479                                               None    (None, None)   \n",
       "1480                                               None    (None, None)   \n",
       "1481                                               None    (None, None)   \n",
       "1482                                               None    (None, None)   \n",
       "1483                                               None    (None, None)   \n",
       "1484                                               None    (None, None)   \n",
       "1485                                               None    (None, None)   \n",
       "1595  Operator: This does conclude todays call and ...     (98, 12988)   \n",
       "1596                                               None    (None, None)   \n",
       "1597                                               None    (None, None)   \n",
       "\n",
       "     word_range_q_and_a  word_count_pres  word_count_q_and_a  \n",
       "4          (1699, 1882)             1669                 184  \n",
       "6          (1445, 1592)             1415                 148  \n",
       "489      (17235, 17258)            17212                  24  \n",
       "604        (2501, 2523)             2482                  23  \n",
       "699        (None, None)                0                   0  \n",
       "700        (None, None)                0                   0  \n",
       "701        (None, None)                0                   0  \n",
       "702        (None, None)                0                   0  \n",
       "747        (8746, 8766)             8628                  21  \n",
       "883        (None, None)                0                   0  \n",
       "884        (None, None)                0                   0  \n",
       "885        (9614, 9627)             9591                  14  \n",
       "886        (9623, 9637)             9598                  15  \n",
       "1199       (None, None)                0                   0  \n",
       "1201       (None, None)                0                   0  \n",
       "1202       (None, None)                0                   0  \n",
       "1478       (None, None)                0                   0  \n",
       "1479       (None, None)                0                   0  \n",
       "1480       (None, None)                0                   0  \n",
       "1481       (None, None)                0                   0  \n",
       "1482       (None, None)                0                   0  \n",
       "1483       (None, None)                0                   0  \n",
       "1484       (None, None)                0                   0  \n",
       "1485       (None, None)                0                   0  \n",
       "1595     (12989, 13001)            12891                  13  \n",
       "1596       (None, None)                0                   0  \n",
       "1597       (None, None)                0                   0  "
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# df['word_range_pres']\n",
    "\n",
    "(df[df['word_count_q_and_a'] <= 200]) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "066d5932",
   "metadata": {
    "scrolled": false
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "840e18b6",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "0ba90f2b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "New columns added and CSV saved.\n"
     ]
    }
   ],
   "source": [
    "\n",
    "# Optionally save the updated DataFrame to a new CSV\n",
    "df.to_csv(\"/Users/marcosmaldacena/Downloads/Thesis Data/2014_transcripts_with_additional_cols.csv\", index=False)\n",
    "\n",
    "print(\"New columns added and CSV saved.\")\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "aca5e874",
   "metadata": {},
   "outputs": [],
   "source": [
    "path = \"/Users/marcosmaldacena/Downloads/Thesis Data/transcripts_with_additional_cols.csv\"\n",
    "\n",
    "df2 = pd.read_csv(path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "22133173",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "     ticker  year  quarter                 date  \\\n",
      "0      DELL  2014        1  2014-04-23 14:21:06   \n",
      "1      DELL  2014        2  2014-07-23 15:32:03   \n",
      "2      DELL  2014        3  2014-10-22 15:06:03   \n",
      "3      DELL  2014        4  2015-01-30 16:24:09   \n",
      "4      ERIE  2014        1  2014-05-02 16:58:07   \n",
      "...     ...   ...      ...                  ...   \n",
      "1825    XEL  2014        4  2015-01-30 05:28:07   \n",
      "1826    XOM  2014        1  2014-05-01 17:43:11   \n",
      "1827    XOM  2014        2  2014-07-31 16:01:02   \n",
      "1828    XOM  2014        3  2014-10-31 17:59:07   \n",
      "1829    XOM  2014        4  2015-02-02 14:41:04   \n",
      "\n",
      "                                                content  \\\n",
      "0     Executives: Anthony T. Takazawa  Vice Preside...   \n",
      "1     Executives: Tony Takazawa - Vice President, Gl...   \n",
      "2     Executives: Tony Takazawa - VP, Global IR Joe ...   \n",
      "3     Executives: Tony Takazawa - VP, Global IR Joe ...   \n",
      "4     Executives:  Scott Beilharz  VP-Capital Manag...   \n",
      "...                                                 ...   \n",
      "1825  Executives: Paul Johnson - VP of IR Ben Fowke ...   \n",
      "1826  Executives:  David Rosenthal  VP, IR and Secr...   \n",
      "1827  Executives: David S. Rosenthal - Vice Presiden...   \n",
      "1828  Executives:  Jeffrey Woodbury  VP, IR and Sec...   \n",
      "1829  Executives: Jeff Woodbury - VP, IR and Secreta...   \n",
      "\n",
      "                                          presentations  \\\n",
      "0     Operator: Good morning, and welcome to the EMC...   \n",
      "1     Operator: Good morning and welcome to the EMC ...   \n",
      "2     Operator: Good morning and welcome to the EMC ...   \n",
      "3     Operator: Welcome. Good morning and welcome to...   \n",
      "4     Operator: Good morning and welcome to the Erie...   \n",
      "...                                                 ...   \n",
      "1825  Operator: Good day everyone. Welcome to the Xc...   \n",
      "1826  Operator: Good day everyone and welcome to thi...   \n",
      "1827  Operator: Good day, and welcome to the Exxon M...   \n",
      "1828  Operator: Good day, and welcome to the ExxonMo...   \n",
      "1829  Operator: Good day, everyone and welcome to th...   \n",
      "\n",
      "                                                    Q&A word_range_pres  \\\n",
      "0     Operator: Thank you. Well begin the question-...     (121, 7595)   \n",
      "1     Operator: Thank you. We will begin the questio...      (84, 5590)   \n",
      "2     Operator: Thank you. Our first question comes ...      (80, 5066)   \n",
      "3     Operator: Certainly, one moment. Our first que...      (86, 5996)   \n",
      "4     Operator: Thank you. [Operator Instructions]\\n...      (30, 1698)   \n",
      "...                                                 ...             ...   \n",
      "1825  Operator: Thank you very much [Operator Instru...      (54, 2764)   \n",
      "1826  Operator: Thank you Mr. Rosenthal. The questio...      (56, 2626)   \n",
      "1827  Operator: [Operator Instructions] We'll go fir...     (109, 2510)   \n",
      "1828  Operator: Thank you Mr. Woodbury [Operator Ins...      (92, 2683)   \n",
      "1829  Operator: Thank you. [Operator Instructions] W...      (90, 3006)   \n",
      "\n",
      "     word_range_q_and_a  word_count_pres  word_count_q_and_a  \n",
      "0         (7596, 11447)             7475                3852  \n",
      "1         (5591, 10348)             5507                4758  \n",
      "2          (5067, 9837)             4987                4771  \n",
      "3          (5997, 9597)             5911                3601  \n",
      "4          (1699, 1882)             1669                 184  \n",
      "...                 ...              ...                 ...  \n",
      "1825       (2765, 6770)             2711                4006  \n",
      "1826       (2627, 9931)             2571                7305  \n",
      "1827      (2511, 10070)             2402                7560  \n",
      "1828       (2684, 9829)             2592                7146  \n",
      "1829      (3007, 10272)             2917                7266  \n",
      "\n",
      "[1830 rows x 11 columns]\n"
     ]
    }
   ],
   "source": [
    "print(df2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "f1de4689",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Q1: Thanks so much. Good afternoon, guys and let me start by saying Brian, you will very much be missed, but Allison congratulations, Im not sure if youre there, but looking forward to working with you more closely and also welcome aboard Pat, looking forward to getting to know you better. Maybe I start with sort of how was your first 50 days has been, any thing surprising? Whats your initial read of the company and the potential long-term growth trajectory here?\n",
      "A1: Well, as I  when I joined the company back in September, I was working excited about the technology and the opportunity that this product can make a better mix in the lives of patients that use it. And I guess what Ive learned over the last 50 years that it is more exciting than when I joined. Im very existed about the product, the technology and really focus on market adoption of this technology for anyone with Type 1 diabetes. This organization is tremendously focused on capitalizing on this opportunity and Im very excited to be here and also congratulate Allison on her promotion to CFO and spending some time on the road with her meeting all of you.\n",
      "Danielle Antalffy -\n",
      "\n",
      "Q2: Great. Thanks for that. And then Pat, I was hoping, or Brian I was hoping to get a little bit more granularity on the [UNA] issue and revolution there. Guys, can you talk about number one, what that equates you in annual sales in your view? If I remember correctly I think you characterize it previously in the $10 million to $50 million range, so if you could confirm that?\n",
      "A2: \n",
      "\n",
      "Q3: Yes. Danielle, its Brian, so thank for that, thank you for your warm words. Initial I can tell over the last few months, the team has worked extremely hard and theres been a lot of conversations have happened between the payer, the distributor and internally we try to ultimately figure what was the best way to resolve it. I think in the end we come through with a couple of changes specifically around this, form that we had talked about previously that will allow for a brand name of the product to be included on the form which should allow to be able to eliminate I think all of the confusion that existed in the marketplace. So, were pleased with that. As you can imagine with any change that needs to go through large organization thats take a little for it to go through, and so, thats why we continue to expect that weve seen for example, in October -- still some impact on the new patients starts front. But it seem like that will dwindle now over the course of the coming weeks and we think it will be a non-issue as we turn the calendar year into 2015. As we talk about last quarter, we have built in to the change in the revenue guidance, the full impact to this for the full year and I think as we given the guidance for this quarter of $76 million to $81 million, thats including all of the impacts that we expect to have in Q4 as well. Obviously, as you think forward to 2015 there will be reorder impact because those people wont have started yet or they have just started, but I think well be able mitigate most of it.\n",
      "Danielle Antalffy -\n",
      "A3: \n",
      "\n",
      "Q4: All right. Thanks so much.\n",
      "Raj Denhoy \n",
      "A4: \n",
      "\n",
      "Q5: Hi, good afternoon. Maybe I was talking little bit on Danielles question, but with so much change in the senior management over such a short period of time variable it will raise questions and people will ask whether there is something perhaps more to this than simply Brian you moving on and the Board wanted to make a change at the CO levels. So I dont know if theres anything else you can maybe offer those Pat or Brian about share amount of change at the senior level in such a short period of time?\n",
      "A5: I can tell you from my side Raj, for me and Ive obviously been here in Insulet for about six years. Its been a great ride. Id loved every minute of this company and I remained very passionate about what we do and what we do and how we help folks. You see it every single day I can give you an example of running into a kid on my sons 10-year old basketball team this pass weekend. And that doesnt change for me. For me personally it was  I started to have some conversations earlier this year, thinking about what was next and what was the right time for me to potentially take on additional opportunities and see if theyre either here at Insulet or elsewhere. And this just seems like the appropriate time for me to kind of make that next step of transition and move on. I think Pat, I can tell you for being here the last 50 days and watching Pat in action. He spend inordinate amount of time getting to know people, getting to know this company, not jump in the conclusions, really trying to understand whats going on here and I think his track records speak for himself and hes going to make a very, very positive impact in this business. And so, I look forward to still being here for the next couple of months and helping the company through and then watching it from the side lines, but obviously have some very vested interest and how the business continues to do with this lot of relationships from me both internally and externally and\n",
      "\n",
      "Q6: Yes. And I guess, I would say that Ive been very impress with the organization since I joint 50 days ago and for me it was an opportunity as Id say to some of my friends, I just went to retirement and decided to get back into the saddle and really enjoy running  I enjoyed running slide deck and Im enjoying doing what Im doing here. And I think the opportunities are similar, that there are challenges in every organization, but there are certain things that we can do better, and Im focused on converting this market to Standard of Care with the OmiPad product. I think its an exciting technology. There are obviously obstacles and you have knocked down one at a time, but were focused on making that happen.\n",
      "Raj Denhoy \n",
      "A6: \n",
      "\n",
      "Q7: Great. Maybe I can ask two specific follow-up questions. First to you Pat. Youve talked about  youve talk about diabetes but less about perhaps drug delivery and that seems to have been perhaps an involving part of the story that could potentially get larger, much larger over time and Im curious if you any thoughts around that? Might be the timeline that sounds or perhaps lengthen a little bit in terms of Amgen deal and also the Type 2 products, so I dont know if there anything you comment around that?\n",
      "A7: \n",
      "\n",
      "Q8: And Raj, its Brian. I do have a couple of things. One, I dont think theres anything that we said so far that you should takeaway thing, the timeline for the Amgen product has changed. If anything the fact that on their earnings call last week they presented this new product, talk about it first time publicly, showed the picture of the product. If anything I think shows that theyre feeling extremely confident that were going to get to the finish line and our timeline on that has always been thinking that they were going to have a Q4 approval and Q4 has done yet. In the Lilly case, weve originally been working towards a plan where we would be able to file the 10-K and get clearance and Lilly wanted to use cleared product to drive the clinical. The FDA provide us some feedback as we are working through them kind of collaboratively around human factor testing that they wanted us to just reverse that and kind of do in the different order. So, it is different and that we wont have to file 10-K file which would have allowed us to potentially sell a little bit on the side, while Lilly was going through their process that said, from the overall timeline of the product thats really not changed, it just reordered.\n",
      "Raj Denhoy \n",
      "A8: \n",
      "\n",
      "Q9: Okay. And then, sorry, just last one, just on gross margins, you mentioned low 60% for the U.S. How much more is left there? I think you have talked about kind of getting into the low 60s with the Gen2 where the current generation pod, how much left do you think there is in driving that gross margin higher?\n",
      "A9: Personally I think theres a lot of that. I mean, I think that there is  Im sure at some point theres a theoretical feeling, but I said to different people at different times. I certainly Im not willing to  you put us feeling on our ability to gain leverage in the business. I mean, we should be able to continue to drive as the business gets bigger and bigger and we add more lines, more and more efficiencies that should be able to drive the cost of different components done and be able to spread out the overhead even more. And so, I think as we looked at this quarter, we gained a couple hundred basis points on the U.S. OmniPod basis. We lost a little bit on our consolidated margin when you look at international share in the neighborhood mix. I think when we look at Q4 to gain a couple of hundred points more of margin, its absolutely achievable. And hopefully all of that close to the consolidated, but again, that will just depend a little bit upon mix of the different components of the business.\n",
      "Raj Denhoy \n",
      "\n",
      "Q10: Thats helpful, and you will be miss,\n",
      "A10: Thanks, Raj.\n",
      "Ben Andrew -\n",
      "\n",
      "Q11: Good afternoon. And Ill add my congratulations and also to everybody thats staying with the company, and Brian, we will miss you. Two questions I guess from me, first, can you talk a little bit about the new patient add trajectory in Q3 and whats implied in Q4, was it plus minus 20% or whatever detail you can give us there. And then, whats the neighborhood diabetes revenue number for the quarter or maybe a percentage there if we can?\n",
      "A11: Yes, sure, Ben, its Brian. So a couple of things in new patients starts, I think as Pat mentioned in his remarks I think were seeing some nice productivity uptick for the new territories where weve added the provable third man in form of kind of this KAM or territory associate kind of role. Overall, we saw probably somewhere about 5% to 10% sequential increase in new patient starts from Q2 to Q3. Still on the trajectory I would tell you a kind of somewhere in the 15% to 20% range overall, new patients starts year-over-year and the trajectory still seems very solid here as where month and few days into the fourth quarter. So I think everybody is feeling good about that and obviously the payer issue kind of being put to bed. I think allows everybody to feel that much more confident as we end this year and look forward into 2015. On the neighborhood side, neighborhood, obviously we lapse competitive bidding this year in the third quarter that was July 1 of 2013 when CMS kind of really significantly reduced the pricing of blood glucose testing supplies. The neighborhood business was up slightly in Q3 on year-over-year basis, probably a couple percentage points. Again, absolutely kind of filling their role and doing a good job, only difference as we have seen in settling a gross margin basis has come down a little bit as the mix of the business has changed and obviously the lower pricing overall from blood glucose testing strips.\n",
      "Ben Andrew -\n",
      "\n",
      "Q12: Okay. And then Pat maybe a question for you that I think weve all kind of looked at over the years, why is  given that only 30% of people are using insulin pumps there is obviously reasons for that. What do you think is the bottlenecks to adoption that Insulet can address them here that perhaps it wasnt addressing effectively before and what are the real levers that you guys can bring operationally to try to accelerate that?\n",
      "A12: \n",
      "\n",
      "Q13: I think there is a number of atleast my initial read on the whole insulin market are Type 1 diabetes market. You have certainly those that are in the multiple daily injections and mostly patients start out in that therapy and then move over to being considered for pump and pump therapy. And I think as weve done market research into the market, it appears that there is a large number of MDI patients that would never consider a pump if they had to use the current conventional pumps, but when provided with the opportunity to use OmniPod the uptake or the interest level is exceedingly high. So I would say what we need to do is focus on the marketing message through the endocrinologists and getting more MDI patients converted to the OmniPod technology. So I think from my perspective, its really leveraging the -- sales force presence in the field and focusing on those high prescribers. And as I said earlier if you look at the number of patients below 18 this is where the product really I think is very good for the kids and their parents to manage these patients with type-1 diabetes. So focusing on that market segment I think will pay great dividends.\n",
      "Ben Andrew -\n",
      "A13: \n",
      "\n",
      "Q14: Were the things the company wasnt doing effectively before from that marketing message to end those or is this just simply going to require a fair bit more of spending whether at times sales people or marketing dollars to accomplish.\n",
      "A14: \n",
      "\n",
      "Q15: Well I think its fair to say that in order to grow were going to have to add sales and marketing resources to get the message out and to have adequate coverage in the market place. When I compare sort of what we spent at Cytyc at the same level of $300 million in revenue versus where we are today, at\n",
      "A15: \n",
      "\n",
      "Q16: Im not prepared to give you exactly what that looks like today because Im still more struggling to do that process, but I think its fair to say that were going to add additional sales from marketing resources.\n",
      "Ben Andrew -\n",
      "A16: \n",
      "\n",
      "Q17: Great. Thank you.\n",
      "William J. Plovanic  Canaccord Genuity,\n",
      "A17: \n",
      "\n",
      "Q18: Thanks, good evening.\n",
      "A18: \n",
      "\n",
      "Q19: Hey Bill, how are you?\n",
      "William J. Plovanic  Canaccord Genuity,\n",
      "A19: \n",
      "\n",
      "Q20: Good. So Im on the airport side theres some background noise. You know saying welcome Pat, congrats to Allison and Brian definitely missed. Most of my questions have been asked but this time Im going to ask more pointed questions. Just it sounds you are kind of still viewing things that sounds like but as we think about 2015 and the current revenue expectations and even profitability expectations out there, I mean should we  can we [casually] say you are comfortable with that, it sounds like maybe from an operating standpoint maybe some more investments in sales and marketing, I know you are still 50 days in getting in there, but how should we start thinking about as you put your stamp on the business from 2015 and beyond?\n",
      "A20: Hey Bill, its Brian. Let me take a first crack at some of it and I think were prepared certainly the company as we get into the first quarter will ultimately provide appropriate guidance for 15 but I think there is a couple of takeaways. One is, weve been adding sales resources as we know and kind of these 20 person or so kind of chunks, because it works well from a historically from a manufacturing side for not over taxing the sales management and the infrastructure of the business the reimbursement pieces and the like. And that has worked really well and so again I think one of the things to take away is this kind of again third man in or so that we have put into some of these territories, assuming that although early days keep in mind these folks have only been in the field now for one full quarter. They seem to have some good momentum and productivity behind them that I think is something that the team it works through strategic planning and budgeting here in Q4. Its really trying to figure out how that model works and do we add more  there are certain territory level where it doesnt isnt as effective and really kind of what that planning is. And a lot of the marketing type things you will recall six months ago or so we talked about we hired for the first time an agency of record and digitized to able to come in here and help drive the branding and help I think really push messaging into the healthcare professional community, that talks about pumps make sense for multiple daily injectors, we need to move them on the pumps and this is how you do it. And I think all of that stuff is resonating and as for me one of the things that I shared with Pat when he started was a call -- this in my mind is a really great time for him to kind and join because in a lot of ways its the first chance that this business has had in a long time to play off and its versus [Indiscernible] as you guys know from following this company for a long time we were worried about how running made its action capacity with the old part and now Im going to try to work at getting then new part approved and then the transition of the customer base which took up a big chunk of last year and then this year now we are putting in those building blocks into place. And I think if anything some of the momentum of whats been invested here over the last six to nine months is starting to show some of those dividends. And so I think thats a really exciting thing to be. You know that said, and Bill I think Pat as he kind of keeps that in kind of starts to allude to it, there are absolutely things we can do better. And I think his leadership and his commercial experience and what hes been through along with Pete [Douglin] and his team and the planning effort they are will drive a lot of what makes some of those new investments look like next year.\n",
      "\n",
      "Q21: Yes I think what Brian just discussed and I would also say that Ive spend the majority of my time over the last 50 days being mostly internally focused inside the understanding, manufacturing R&D and then our commercial efforts, but now Im turning my attention to spending more time in the field with the field force and over the next couple of months getting a good flavor of how we execute the sales strategy in the field and would come back here early next year with my assessments and plans for 2015.\n",
      "William J. Plovanic  Canaccord Genuity,\n",
      "A21: \n",
      "\n",
      "Q22: Fair enough thank you. And then some -- questions, just on the I was wondering with the Amgen can you quantify what you believe that market opportunity is and when do we actually start seeing that show up in the business?\n",
      "A22: \n",
      "\n",
      "Q23: Well Neulasta for Amgen is about $4 billion product in the United States. There are I think as Ive done the research about 900,000 patients are used at right every year and it currently in its current form is approved by the FDA. This filing is for use of that product and our OmniPod. I would say it we will assuming it gets approved in the fourth quarter or early next year we expect to receive revenue from it, but its hard to really put a number on the table because it all depends upon how that launch goes for Amgen but I know that they are extremely excited about and we are working very hard with them for a very successful launch.\n",
      "William J. Plovanic  Canaccord Genuity,\n",
      "A23: \n",
      "\n",
      "Q24: \n",
      "A24: \n",
      "\n",
      "Q25: We expect to show that PDM at the ADA Meeting in the next summer in Boston, so we are going to have a coming out party in our home town with that product and would expect to file that in early 2016.\n",
      "William J. Plovanic  Canaccord Genuity,\n",
      "A25: \n",
      "\n",
      "Q26: But you will show that ADA but you will file the PMA  Im sorry the 510(k) in early 2016?\n",
      "A26: \n",
      "\n",
      "Q27: Correct.\n",
      "William J. Plovanic  Canaccord Genuity,\n",
      "A27: \n",
      "\n",
      "Q28: Okay, great. I think thats all\n",
      "A28: \n",
      "\n",
      "Q29: Safe travel, Bill.\n",
      "William J. Plovanic  Canaccord Genuity,\n",
      "A29: \n",
      "\n",
      "Q30: \n",
      "A30: Yes, thats correct. Because again each passing quarter you have to include the reorders or the last reorders if you will for the patients that didnt start the quarter before. So yes my assumption really hasnt changed from what we talked about back last quarter whether which was those about a million and a half of it impacting Q2 probably somewhere in the 3 to 3.5 million range in Q3 and then probably 4 5 or so in Q4 is we start to see the new patient start kind of pipeline ramp up again. No different metrics, right. So 5% to 10% sequential growth Q2 to Q3 when we talked about 20% we are talking year-over-year, right. And the year-over-year we talked about that full kind of nine month period, so on a year-to-date basis which is that so, just to make sure we dont mix and add there. I mean I dont want to comment about actual patient count numbers, Ill just leave it to say that were about 5% to 10% higher sequentially in Q3 than we were in Q2. I dont have all the models in front of me.\n",
      "\n",
      "Q31: I think conceptually we are looking at the market place and basically looking at the drugs that are currently on the market and the opportunity for using the OmniPod as a special drug delivery device for those products whether they are currently on the market or in development, in stack ranking those in terms of opportunity and near term sales growth that we could expect from those type of applications and then putting resources against those opportunities to really capitalize on this use of the OmniPod. I mean, I think from  you can leverage two things. You can leverage the technology which this obviously does and focusing on new sales and marketing to leverage the sales force. So were going to definitely making plans to leverage this technology.\n",
      "A31: Its interesting when you think about like one of the benefits of the product when you think about existing drugs is looking at when certain compounds or things come off a patent for example could be an interesting way, the interesting reason why adding in a delivery device like the OmniPod makes sense. And we keep in mind that, that with a lot of these and even with the Amgen product weve seen it, it takes a few years once from when you sign a deal its ultimately be able to get it to market, because of the process of either maybe a little bit of development, maybe not but then ultimately going through the obviously the FDA process. So Capricor is on the other side that which is  there is the phase 2 product and we are helping them through their clinical trials. Now the reality of when that becomes a commercial product years down the line, but its exciting to be part of that one too and really affect to be part of their filing. So theres a mix of them in the pipeline, Ferring is obviously an approved one in Europe and we have been generating revenue from it. Amgen will be next and then as we continue to add more and more of these projects and we have a couple more on going, well see how those develop and above and be able to drive actual timelines for each one. Just we have about 135 people or so in the field. Right now I think we are still split at 53 territories, right. So that would basically  so 53\n",
      "\n",
      "Q32: Okay, great.\n",
      "A32: \n",
      "\n",
      "Q33: Hey [Tow].\n",
      "A33: Apologize, Im not sure I completely follow that, but were  again, where were heading just and so we stay clear here is on a year-over-year basis weve talked that were looking effectively for 20% year-over-year patient growth, new patients starts and I think everything has been trending close to that number. Were probably little lower than that at the moment, but again if you look at specific issue around the payer thats been one thats been driving it. On a quarter-over-quarter basis, Q2 to Q3, I mentioned a couple of minutes ago that were basically driving between kind of 5% and 10% sequential growth. So those are the two pieces. In regards to the payer issue specifically its an open question, right, because what you seeing with the patients are in some cases they may  if there a chronologist is been saying, look you need to give on pump and unfortunately we cant get this when approved right now, but you got to get another pump, some of those patients may have gone elsewhere. Some may delay their decision. Some wait for the next trip back to the doctor. So, theres our team has done a really good job I think in the commercial side of trying to keep the patients  the pipeline warm if you will and trying to be able to bring these folks openly across the goal line. No one that were able to get this result, but ultimately we have to see how that plays itself out. So, from that perspective I dont think theres any difference. I think when you look at the revenue growth in the business, again, weve always been a midpoint company and when we updated guidance last quarter, the midpoint of that range is 295. If you look at the midpoint of the range that we gave you today is 295. So I dont think theres any real change or difference there at all. I mean, thats overall pipeline, right, so were not talking about just one pair here. Were talking about the overall pipeline and that is absolutely not changed. I mean, the team is continues to do a good job of drive-in referrals and ultimately those referrals turning into new patients starts. So, I think weve seen good momentum in that business overall. My only comment specifically to this one pair is its unclear for patient who is looking start on OmniPod back in May is going to still be there for us to be able to convert in January. I mean, were certainly try, right, but its a little less clear to be to say everybody is willing to wait six, seven, eight months or whatever it is to be able to finally cross the goal line.\n",
      "\n",
      "Q34: Okay, great. Thank you.\n",
      "Mike Rich \n",
      "A34: \n",
      "\n",
      "Q35: Hi. This is Mike Rich calling for Jayson. Can you hear me, okay?\n",
      "A35: How are you?\n",
      "Mike Rich \n",
      "\n",
      "Q36: Hey, guys. Thanks for taking the questions. Most of my questions have been answered. But I just wanted to circle back to a couple of things. First, good color on the partnership with Ypsomed outside of the U.S. I know youre tracking for doubling growth this year, but can you comment on the sales growth outside the U.S. in the quarter or perhaps what percent of sales, international sales were?\n",
      "A36: Not at this point I guess, but as Ypsomed said last week, I mean, theyve seen over their last six months about a 60% or so increase in their business. Were absolutely on track when we look at our international partnerships which will also include GlaxoSmithKline for Canada, to double our international revenue in 2014 versus 2013. And as Pat in his remarks, I think were really excited and hopeful that were going to see reimbursement in France very soon, and France is a really interesting market in Europe. I think its the second largest pump market in Europe, and today we sit with the zero there. So, getting France over the goal line would allow really another really good growth opportunity Ypsomed as they turn the corner into calendar year 2015. But overall, I think the international business has been doing great again. One thing you can point a little  the revenue share is great. There are certainly helping us to drive to net breakeven at the operating level or an operating profit. Its lowers the gross margins slightly, but thats a good trade off.\n",
      "Mike Rich \n",
      "\n",
      "Q37: Got it. Okay. And then is there timeline for OmniPod approval in China?\n",
      "A37: Not anything at this point. I mean, I would tell you that weve continued to kind of work through the regulatory process over there in China. I dont have an update on it. I know that were still need [Ethernet] but its probably some while the companys feeling we get.\n",
      "Mike Rich \n",
      "\n",
      "Q38: Okay. And then lastly sorry, I missed this, but an update on the currently generation like PDM with LifeScan meter?\n",
      "A38: Yes. Were looking to hopefully have approval that. Very soon weve responded to all of the FDAs questions. Most of the questions that the agency came back with actually were more I would say a LifeScan driven and Insulet driven and well see some questions around the various strip and those pieces which our partner has done a great job of responding to and providing the data for. So, were just in the waiting game at the moment. But hopefully well have an answer pretty soon.\n",
      "Mike Rich \n",
      "\n",
      "Q39: Okay. Great. Thank you very much.\n",
      "Jan Wald -\n",
      "A39: \n",
      "\n",
      "Q40: Thank you. And congratulations to Allison, Brian and Pat welcome and good luck. I guess most of my questions has been answered, but let me just ask a couple of more. Maybe taking also on [Dave] question a little bit more on profitability versus investment. Not looking for whats youre going to do, but how do say company moving forward. You company at your stage looks towards profitability but it needs to make investments. How do you see the priority of those two things occurring over the next year to two years?\n",
      "A40: One of the nice things Jan, weve able to find a good balance to both of those in the past, as you could see from the fact that weve been able to balance I think a very strong overall top line growth with getting now operating profitability, $4 million of operating profit excluding up the transition costs is are highest level of operating profit and obviously we continue to feel very bullish about pushing more gross margin to the business. So, I think the business has positioned well to be able to find balance for both those going forward, which is a good spot for the company to be.\n",
      "Jan Wald -\n",
      "\n",
      "Q41: Okay. I guess my next question is in your prepared remarks you mentioned there are more efficiencies that youre going to look for. I think you probably meant to manufacturing? What kinds of things would you be looking to do in manufacturing with us, I guess elsewhere in the business can might improve those  might lead to more efficiencies?\n",
      "A41: Specifically when we talked about, we have the fourth manufacturing line come up and one of the thing that been interesting in our manufacturing processes, with each line were obviously getting smarter of how to make an OmniPod with highest level of quality and most cost effectively possible. And so I think Ive shared in the past that when you look at Line 3 for example, right now its been our efficient line and weve been able to make some small adjustments for like Line 2 for example to make it look Line 3, so that one becomes the lot more efficient. Line 1 for us is probably been  always been our most inefficient line where its highest level of people required and with the lowest capacity. So when Line 4 comes on board for example, its going to mere image Line 3, so well get that efficiency out of the gate and it starts to give us some flexibility to think about how we can better leverage Line 1 for example and therefore spread out overhead cost and look at the amount of direct labor required and those type of things hopefully further bring down the pod price. That plus as we keep moving up the volume spectrum, were able to drive some additional cost components increases from our suppliers, which is also another positive and helping us generate more gross margin. So, those are couple of examples that where more efficiency can be gain.\n",
      "Jan Wald -\n",
      "\n",
      "Q42: Okay. And my last question, on the CGM center, it sounds as if youre still going through some kind of design process, because youre addressing the kinds of issues that would get addressed in design. Any sense of when youre going to be  when it will design for use or some like can you be able move into the clinical?\n",
      "A42: I think weve said, that we said, weve been going to a process obviously the sterilization weve gone through this latest testing we did was earlier on this idea of distance between sensing and dispensing and we think  we got some  we believe some pretty favorable results out of that. So youre right, that is still kind of a design phase if you will. And weve talked about doing some inhuman trial work hopefully sometime early to mid 2015. Ultimately well see where that timeline is driving towards in the second kind of all the [indiscernible] next real indicator to drive the overall timeline of the project. So as we get closer to that point, that probably the next checking time.\n",
      "Jan Wald -\n",
      "\n",
      "Q43: \n",
      "A43: \n",
      "\n",
      "Q44: \n",
      "A44: \n",
      "\n"
     ]
    }
   ],
   "source": [
    "\n",
    "q_and_a_results, _ = process_transcript(transcript2)\n",
    "\n",
    "\n",
    "for i, item in enumerate(q_and_a_results, start=1):\n",
    "    print(f\"Q{i}: {item['question']}\")\n",
    "    print(f\"A{i}: {item['answer']}\")\n",
    "    print()\n",
    "\n",
    "# process_transcript(transcript2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "id": "e8860530",
   "metadata": {},
   "outputs": [],
   "source": [
    "# def process_single_transcript(transcript):\n",
    "#     \"\"\"\n",
    "#     Given a full transcript text:\n",
    "#       1) Extract the strings of executives and analysts.\n",
    "#       2) Extract presentation text (first -> second 'Operator:' gap).\n",
    "#       3) Extract Q&A text (everything after second 'Operator:').\n",
    "#       4) Remove 'Operator:' lines from Q&A text.\n",
    "#       5) Create Q&A pairs.\n",
    "#       6) Gather some metadata.\n",
    "\n",
    "#     Returns a dictionary of results.\n",
    "#     \"\"\"\n",
    "#     # 1) Get execs/analysts from the transcript\n",
    "#     #    (Careful: might raise AttributeError if \"Executives:\" or \"Analysts:\" not found)\n",
    "#     executives, analysts = extract_names(transcript)\n",
    "    \n",
    "#     # 2) Presentation text\n",
    "#     presentation_text = extract_presentation(transcript)\n",
    "#     if presentation_text is None:\n",
    "#         presentation_text = \"\"  # or some default fallback\n",
    "\n",
    "#     # 3) Q&A text\n",
    "#     qa_text = extract_q_and_a(transcript)\n",
    "#     if qa_text is None:\n",
    "#         qa_text = \"\"  # or fallback\n",
    "\n",
    "#     # 4) Remove operator lines from the Q&A portion\n",
    "#     qa_clean = remove_operator_lines(qa_text)\n",
    "\n",
    "#     # 5) Create question-answer pairs\n",
    "#     #    'executives' and 'analysts' are strings; \n",
    "#     #    the function checks for speaker tokens within them.\n",
    "#     qna_pairs = create_qna_pairs(qa_clean, executives, analysts)\n",
    "\n",
    "#     # 6) Build metadata \n",
    "#     num_pairs = len(qna_pairs)\n",
    "\n",
    "#     # We'll track the word count for presentation, \n",
    "#     # plus a list of Q & A word counts.\n",
    "#     presentation_word_count = len(presentation_text.split())\n",
    "\n",
    "#     # For each Q&A pair, count question words and answer words\n",
    "#     q_word_counts = [len(pair[\"question\"].split()) for pair in qna_pairs]\n",
    "#     a_word_counts = [len(pair[\"answer\"].split())   for pair in qna_pairs]\n",
    "\n",
    "#     # We might also want the total words in Q or A\n",
    "#     total_question_words = sum(q_word_counts)\n",
    "#     total_answer_words   = sum(a_word_counts)\n",
    "\n",
    "#     # Word range for the presentation in the entire doc (roughly):\n",
    "#     #   We'll do a naive approach: find how many words come before \"presentation_text\"\n",
    "#     #   in the entire transcript. This is \"best effort\" because \n",
    "#     #   your \"presentation\" is specifically the text between the first and second \"Operator:\".\n",
    "#     #   We'll assume it occurs in the same order in the transcript.\n",
    "\n",
    "#     # Let's create a single string for the entire transcript words:\n",
    "#     full_words = transcript.split()\n",
    "#     pres_words = presentation_text.split()\n",
    "\n",
    "#     # If the presentation_text is definitely a substring, we can try to locate it by words.\n",
    "#     # For simplicity, let's assume it starts at first_operator and ends at second_operator.\n",
    "#     # So let's estimate the word indexes as:\n",
    "#     start_idx = len(transcript[:transcript.find(presentation_text)].split())  # words before presentation\n",
    "#     end_idx = start_idx + len(pres_words) - 1  # inclusive end index\n",
    "\n",
    "#     return {\n",
    "#         \"num_qna_pairs\": num_pairs,\n",
    "#         \"presentation_word_count\": presentation_word_count,\n",
    "#         \"question_word_counts\": q_word_counts,\n",
    "#         \"answer_word_counts\": a_word_counts,\n",
    "#         \"total_question_words\": total_question_words,\n",
    "#         \"total_answer_words\": total_answer_words,\n",
    "#         \"presentation_word_range\": (start_idx, end_idx),\n",
    "#         \"presentation_text\": presentation_text,  # if you need the raw text\n",
    "#         \"qna_pairs\": qna_pairs                   # if you want them\n",
    "#     }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "id": "c09be9a3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'num_qna_pairs': 44,\n",
       " 'presentation_word_count': 2943,\n",
       " 'question_word_counts': [81,\n",
       "  70,\n",
       "  295,\n",
       "  8,\n",
       "  95,\n",
       "  135,\n",
       "  92,\n",
       "  227,\n",
       "  59,\n",
       "  7,\n",
       "  80,\n",
       "  79,\n",
       "  212,\n",
       "  40,\n",
       "  61,\n",
       "  41,\n",
       "  9,\n",
       "  3,\n",
       "  11,\n",
       "  130,\n",
       "  98,\n",
       "  41,\n",
       "  129,\n",
       "  0,\n",
       "  48,\n",
       "  20,\n",
       "  7,\n",
       "  6,\n",
       "  9,\n",
       "  0,\n",
       "  129,\n",
       "  2,\n",
       "  2,\n",
       "  7,\n",
       "  13,\n",
       "  70,\n",
       "  13,\n",
       "  20,\n",
       "  9,\n",
       "  92,\n",
       "  60,\n",
       "  61,\n",
       "  0,\n",
       "  0],\n",
       " 'answer_word_counts': [123,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  273,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  193,\n",
       "  5,\n",
       "  258,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  552,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  192,\n",
       "  275,\n",
       "  0,\n",
       "  462,\n",
       "  0,\n",
       "  6,\n",
       "  190,\n",
       "  53,\n",
       "  89,\n",
       "  0,\n",
       "  112,\n",
       "  250,\n",
       "  126,\n",
       "  0,\n",
       "  0],\n",
       " 'total_question_words': 2571,\n",
       " 'total_answer_words': 3159,\n",
       " 'presentation_word_range': (49, 2991),\n",
       " 'presentation_text': 'Operator: Good day, ladies and gentlemen, and welcome to the Insulet Corporation Q3 2014 |Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to introduce your host for todays call Brian Roberts, CFO. Sir, please begin.\\nBrian K. Roberts: Thank you. Good afternoon, everyone. Thank you for joining us for our third quarter 2014 conference call. Im Brian Roberts, Chief Financial Officer of Insulet, and joining me on the call today is Patrick Sullivan, our President and Chief Executive Officer and Allison Dorval our Vice President and Controller. Before we get started, Id like to remind everyone that our discussion today may include forward-looking statements as defined under the securities laws. We intend these forward-looking statements to be covered by the Safe Harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and are making this statement for purposes of complying with those Safe Harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. There are risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Information concerning the companys potential risks and uncertainties is highlighted in the companys press release issued earlier today and in the Risk Factors section of the companys SEC filings, including the companys Annual Report on Form 10-K for the year ended December 31, 2013. These risk factors apply to our oral and written comments. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. Id also like to remind you that the guidance were offering today represents a point-in-time estimate of our future performance. Youll find a link to the webcast of this call, as well as to todays press release, at myomnipod.com in the Investors section. And now, let me take a minute to introduce you to Patrick Sullivan. As you know Pat joined Insulet on September 17 as President and CEO and brings to Insulet over 30 years of Executive leadership experience including a 13 year period as Chairman, President and CEO of Cytyc Corporation. Pat led Cytyc to exceptional growth as revenues increased from $4 million to more than $750 million through a combination of organic growth and strategic acquisitions culminating in its acquisition by Hologic in 2007. His leadership and experience is a great addition to Insulet as the company enters its next phase of growth. Welcome aboard Pat.\\nPatrick J. Sullivan : Thanks, Brian and good afternoon everyone and thank you for joining us on the call today. Im very excited and honored to have the opportunity to work with such an innovative and progressive company. Over the last 50 days Ive had the opportunity to gain a much deeper understanding of our company, the industry and the opportunities that lie ahead. As I learn more, my enthusiasm for this business and its future continues to grow. Im looking forward to finishing out 2014 and driving our strategic initiatives in 2015 and beyond. As we look towards 2015, its clear that we are building off a very solid foundation as the existing business continues to perform. We delivered $70 million of topline revenue in the third quarter representing a 23% increase year-over-year. In my short time here, Ive been impressed with the passion of our commercial team as they continued to build our presence with both the existing and new healthcare practices to drive adoption of the OmniPod. Our product helps people improve control over their diabetes providing them the freedom to enjoy life. In fact, about 70% of our initial patient starts are new to insulin pumping. These customers report that the easy to use water proof and tubeless design is appealing as they gained the benefits of insulin pumping without the hassle of conventional pumps. This is especially true in the age 18 and under group. Approximately 40% of our new patient starts in the third quarter or in this important age group. While our annualized attrition continues at a rate of about 9% we know that the rate of attrition in those 18 and under is only about 5%. Once kids and their parents experience the freedom of the OmniPod they do not change. Critical to our ability to convert multiple daily injectors to the OmniPod is for us to deepen our relationship with endocrinologist and clinical diabetes educators. In addition to discreet size the pod, healthcare professionals continue to cite the updated insulin on board calculator, the simplicity of a low assembly system and life style convenience as the key reasons why they prescribe the product. They clearly expect our sales professionals to be readily available to assist them as required in adopting the OmniPod. To that end over this year we added approximately 20 new commercial team members to increase our presence and ability to serve healthcare professionals. Weve added a new role that we refer to as Key Account Manager or KAMS who are permanently passed with ensuring a high level of customer service to critical existing accounts, which will allow our territory sales reps to spend more time with new prescribers. The early returns for these new resources are positive. Territories with Cams have experienced a 15% average increase from referrals since we added them in Q2. As these resources continue to gain experience, we believe overall productivity will increase further and expect we will add additional commercial resources early next year. Last quarter, you will recall that we discussed an issue with a significant payor who made changes to the Insulin pump coverage guidelines which were not eliminating reimbursement for the OmniPod did cause a lot of confusion across the country. Over the past few months, we have worked diligently with this payer and our distributor partner to serve this payer to rectify the problem. We are pleased to report that we believe the issue is behind us and will not impact new patient starts in 2015. The payors revised its process in a manner that we believe will both eliminate the confusion surrounding OmniPod reimbursement eligibility and keep OmniPod consistent with traditional insulin pumps in terms of required documentation. The payor is currently rolling out to revise process and forms and given the timing of the roll out we expect new patient starts to be impacted through Q4 but declining with a declining impact each month. On the international side our business our business continues to grow as well as we remain on track to double for calendar year 2014. As many of you may have seen our European partner, Ypsomed released a six month results ended September 30, 2014 last week. Those results showed a 60% sales increase for the OmniPod system driving nearly all of the growth in the direct diabetes business. And looking at the success we see continuous share gains across Europe with countries such as the Netherlands, Austria, the U.K. and Switzerland in the mid to upper teens. And as we look forward, we believe the opportunity for growth remains high as Ypsomed continues to add share in other markets such as Germany, Sweden, Finland and opens new market such as Italy which we lost last quarter and France which we hope to launch early next year once reimbursement is secured. Although we generate lower gross margins on our international partnerships this business continues to drive our operating margin improvement as increased revenues require only minimal incremental operating expenses. In Q3, we manufactured more than 3 million pods for the first time in a quarter, and more importantly the quality of the product from Flextronics has never been higher as yields have improved to greater than 98%. This improved quality has translated to reduced cost through our customer support team and higher confidence in the field. We are in the process of finishing line for Flextronics and expect to put it in service early next year. Additionally, our record production drove incremental gross margin improvement in the quarter as U.S. product margins are now in the low 60s and consolidated gross margins increased by more than a 100 basis points to 51%. On a consolidated basis gross margins continued to be impacted slightly by product mix within our neighborhood subsidiary and increasing international market share. Overall, we have improved gross margins by more than 700 basis points since the new OmniPod was launched. Gross margins will continue to improve in the fourth quarter as additional OmniPod cost savings further reduce the cost per pod. Im very impressed with our manufacturing capabilities endured as one of our core competencies. And in our deed we need to continue to enhance our existing product or development, new products that meet the customer needs. Ive spend a significant amount of my time to date at Insulet gaining a full understanding of our research and development efforts. At the top of the priority list is our new PDM initiative. The goal of this new PDM is to provide our users with more modern looking touch screen devices that with a cleaner user interface as well as incorporate blue tooth capabilities to allow us to solve some of the data management challenges facing the industry today. We see the blue tooth capability as one of the most important enhancements as it will allow two way communications with other platforms such as Dexcoms chair platform recently approved by the FDA. Once the PDM is approved we look forward to sharing data with Dexcom to allow our common users improve data viewing capabilities. While the work on our PDM moves forward, we are also making progress in our activities to integrate a CGM sensor into the OmniPod. Im particularly interested in this long term initiative as it is clear that a one item on the body and one hand held solution is very attractive for our customers, healthcare professionals and managed care payors alike. Were the only company with a capability to bring these two tremendous technologies into one easy to use platform. Weve recently completed additional testing around proximity of sensing and dispensing that gives us increased confidence in our integrated CGM solution. During the quarter, we also received feedback from the FDA regarding our planned approach in partnership with Eli Lilly for our OmniPod system specifically designed for use with U-500 insulin. Our initial approach with Lilly was for us to file our 510(k) gain approval and then complete our clinical trial with -- to update their labeling. The FDA however has informed us that they now prefer the clinical trial to be completed prior to our F 510(k) submission. We are working closely with Lilly to revise the timeline for our clinical study and to file for clearance. We anticipate the clinical commuting mid next year. There is a number of highly resistant people living with type-2 diabetes is increasing daily, the need for this product continues to grow and both companies remain committed and enthusiastic about this project. Finally, last week Amgen publicly discussed the first time the Neulasta on-body delivery system that leverages the OmniPod technology. This one of a kind system will allow a patient to leave the doctors office with an activated delivery device programmed to deliver relapse of the following day. We are working closely with Amgen for their approval and subsequent launch of this product. In addition to Amgen and our ongoing partnership with Ferring pharmaceuticals, our newest partner Capricor Therapeutics announced last month to start a clinical program for the drug and Cenderitide to treat post acute heart fail using our drug delivery system. We will provide product development, product management and design control activities in partnership with Capricor in addition to providing clinical product for their clinical trial. We look forward to assisting in this exciting opportunity. With those comments let me turn the call back to Brian for additional details on our financial performance.\\nBrian K. Roberts: Thanks Pat. Consolidated revenue increased by 23% year-over-year to $75 million for the quarter ended September 30, 2014 from $61.1 million in the same period last year. For the nine months of 2014 consolidated revenue was $216.2 million compared to $178.6 million for the first nine months of 2013 a year-over-year increase of 21%.  Gross profit increased by 39% in the third quarter to $38 million as compared to a gross profit of $27.4 million in the third quarter of last year. Consolidated gross margins of 51% represent a 600 basis point improvement over the third quarter of 2013. As we look towards the fourth quarter and early 2015, we expect further improvements in our consolidated gross margins through a combination of additional component price reductions and incremental overhead leverage with the start of the fourth manufacturing line. Gross profit for the first nine months of 2014 was $106.6 million, an increase of $27.2 million or 34% as compared to $79.4 million in the first nine months of 2013. Operating expenses decreased by $3.8 million or 8% year-over-year to $40.9 million in the third quarter of 2014 from $44.7 million in the prior year. This quarters operating expenses include approximately $7 million of compensation charges related to the CEO transition in September most of which is non cash. Excluding those charges operating expenses would have been about $34 million in Q3. Last years third quarter operating expenses also included approximately $10 million of one time charges related to the settlement of the patent litigation of Medtronics. Fourth quarter operating expenses are expected to be in a range of $36 million to $39 million including approximately $3 million of remaining stock compensation charges associated with the CEO transition. Operating expense were $116.7 million for the first nine months of 2014 compared to $108.7 million for the first nine months of 2013. Operating loss was $2.9 million compared to $17.3 million in the prior year, an improvement of over 80%. Excluding the one-time compensation charges, we would have reported an operating profit of approximately $4 million in the third quarter of 2014. Interest and other expense was $7.9 million in the third quarter compared to $4 million last year. In June, we issued approximately $201 million of 2% convertible senior notes maturing in June 2019, and used approximately $160 million of the net proceeds to repurchase the $115 million of the outstanding 3.75% notes that were due in June of 2016. In July, we retired the remaining outstanding 3.75% notes in exchange for $28.8 million in cash and approximately 350,000 shares of common stock. We recorded a loss on the extinguishment of debt of approximately $4.3 million in the third quarter relating to that transaction. Net interest and other expense was $35.9 million for the first nine months of 2014 including a total of approximately $23 million of expense related to the early extinguishment of the 3.75% convertible senior notes. That compares to $12.9 million for the first nine months of 2013. Going forward, we expect to record interest expense related to the 2% notes of approximately $3 million per quarter comprised of $1 million in cash interest expense and $2 million in non-cash interest expense. Excluding the impact of the extinguishment of debt and the one-time compensation charges they reached breakeven results of the net income line and on an earnings per share basis in the third quarter of 2014. Including these items our net loss for the third quarter was $10.8 million or $0.19 per share as compared to net loss of $21.3 million or $0.39 per share for the third quarter of last year. Net loss for the first nine months of 2014 was $46.1 million or $0.83 per share compared to $42.5 million or $0.79 per share for the first nine months of 2013. Our cash and cash equivalents balance was $146.4 million at September 30 compared to $149.7 million at December 31. As of September 30, we had approximately 56 million common shares outstanding. Turning to guidance, we have further refined our 2014 revenue expectations to $292 million to $297 million translating to a range of expected revenue of $76 million to $81 million for the fourth quarter. That takes into consideration the impact of the payer issue weve discussed. Lastly, after six rewarding years, Ive made the difficult decision to resign my position at Insulet. Im very proud of all that has been accomplished over my time here including a 10x increase revenue from approximately $30 million in 2008 and only $300 million this year, and even larger increase in market cap to over $2.2 billion and achieving operating profitability. More importantly, Ive had the privilege to speak with many of our customers and see the impact were making their life each and every day and to work with an incredibly talented team of people. Its with even greater pride that I turn the CFO range over the Allison Dorval, who has been my right hand since by first day. Many of you have the opportunity to meet Allison in various investor conferences over the past couple of years and Im more than confident that she would do a tremendous job for you, our shareholders, our customers and our colleagues. Ill stay as an employee of Insulet through the end of the year to ensure smooth transition. And with that, operator, please open the call for questions\\n',\n",
       " 'qna_pairs': [{'question': 'Thanks so much. Good afternoon, guys and let me start by saying Brian, you will very much be missed, but Allison congratulations, Im not sure if youre there, but looking forward to working with you more closely and also welcome aboard Pat, looking forward to getting to know you better. Maybe I start with sort of how was your first 50 days has been, any thing surprising? Whats your initial read of the company and the potential long-term growth trajectory here?',\n",
       "   'answer': 'Well, as I  when I joined the company back in September, I was working excited about the technology and the opportunity that this product can make a better mix in the lives of patients that use it. And I guess what Ive learned over the last 50 years that it is more exciting than when I joined. Im very existed about the product, the technology and really focus on market adoption of this technology for anyone with Type 1 diabetes. This organization is tremendously focused on capitalizing on this opportunity and Im very excited to be here and also congratulate Allison on her promotion to CFO and spending some time on the road with her meeting all of you.\\nDanielle Antalffy -'},\n",
       "  {'question': 'Great. Thanks for that. And then Pat, I was hoping, or Brian I was hoping to get a little bit more granularity on the [UNA] issue and revolution there. Guys, can you talk about number one, what that equates you in annual sales in your view? If I remember correctly I think you characterize it previously in the $10 million to $50 million range, so if you could confirm that?',\n",
       "   'answer': ''},\n",
       "  {'question': 'Yes. Danielle, its Brian, so thank for that, thank you for your warm words. Initial I can tell over the last few months, the team has worked extremely hard and theres been a lot of conversations have happened between the payer, the distributor and internally we try to ultimately figure what was the best way to resolve it. I think in the end we come through with a couple of changes specifically around this, form that we had talked about previously that will allow for a brand name of the product to be included on the form which should allow to be able to eliminate I think all of the confusion that existed in the marketplace. So, were pleased with that. As you can imagine with any change that needs to go through large organization thats take a little for it to go through, and so, thats why we continue to expect that weve seen for example, in October -- still some impact on the new patients starts front. But it seem like that will dwindle now over the course of the coming weeks and we think it will be a non-issue as we turn the calendar year into 2015. As we talk about last quarter, we have built in to the change in the revenue guidance, the full impact to this for the full year and I think as we given the guidance for this quarter of $76 million to $81 million, thats including all of the impacts that we expect to have in Q4 as well. Obviously, as you think forward to 2015 there will be reorder impact because those people wont have started yet or they have just started, but I think well be able mitigate most of it.\\nDanielle Antalffy -',\n",
       "   'answer': ''},\n",
       "  {'question': 'All right. Thanks so much.\\nRaj Denhoy ', 'answer': ''},\n",
       "  {'question': 'Hi, good afternoon. Maybe I was talking little bit on Danielles question, but with so much change in the senior management over such a short period of time variable it will raise questions and people will ask whether there is something perhaps more to this than simply Brian you moving on and the Board wanted to make a change at the CO levels. So I dont know if theres anything else you can maybe offer those Pat or Brian about share amount of change at the senior level in such a short period of time?',\n",
       "   'answer': 'I can tell you from my side Raj, for me and Ive obviously been here in Insulet for about six years. Its been a great ride. Id loved every minute of this company and I remained very passionate about what we do and what we do and how we help folks. You see it every single day I can give you an example of running into a kid on my sons 10-year old basketball team this pass weekend. And that doesnt change for me. For me personally it was  I started to have some conversations earlier this year, thinking about what was next and what was the right time for me to potentially take on additional opportunities and see if theyre either here at Insulet or elsewhere. And this just seems like the appropriate time for me to kind of make that next step of transition and move on. I think Pat, I can tell you for being here the last 50 days and watching Pat in action. He spend inordinate amount of time getting to know people, getting to know this company, not jump in the conclusions, really trying to understand whats going on here and I think his track records speak for himself and hes going to make a very, very positive impact in this business. And so, I look forward to still being here for the next couple of months and helping the company through and then watching it from the side lines, but obviously have some very vested interest and how the business continues to do with this lot of relationships from me both internally and externally and'},\n",
       "  {'question': 'Yes. And I guess, I would say that Ive been very impress with the organization since I joint 50 days ago and for me it was an opportunity as Id say to some of my friends, I just went to retirement and decided to get back into the saddle and really enjoy running  I enjoyed running slide deck and Im enjoying doing what Im doing here. And I think the opportunities are similar, that there are challenges in every organization, but there are certain things that we can do better, and Im focused on converting this market to Standard of Care with the OmiPad product. I think its an exciting technology. There are obviously obstacles and you have knocked down one at a time, but were focused on making that happen.\\nRaj Denhoy ',\n",
       "   'answer': ''},\n",
       "  {'question': 'Great. Maybe I can ask two specific follow-up questions. First to you Pat. Youve talked about  youve talk about diabetes but less about perhaps drug delivery and that seems to have been perhaps an involving part of the story that could potentially get larger, much larger over time and Im curious if you any thoughts around that? Might be the timeline that sounds or perhaps lengthen a little bit in terms of Amgen deal and also the Type 2 products, so I dont know if there anything you comment around that?',\n",
       "   'answer': ''},\n",
       "  {'question': 'And Raj, its Brian. I do have a couple of things. One, I dont think theres anything that we said so far that you should takeaway thing, the timeline for the Amgen product has changed. If anything the fact that on their earnings call last week they presented this new product, talk about it first time publicly, showed the picture of the product. If anything I think shows that theyre feeling extremely confident that were going to get to the finish line and our timeline on that has always been thinking that they were going to have a Q4 approval and Q4 has done yet. In the Lilly case, weve originally been working towards a plan where we would be able to file the 10-K and get clearance and Lilly wanted to use cleared product to drive the clinical. The FDA provide us some feedback as we are working through them kind of collaboratively around human factor testing that they wanted us to just reverse that and kind of do in the different order. So, it is different and that we wont have to file 10-K file which would have allowed us to potentially sell a little bit on the side, while Lilly was going through their process that said, from the overall timeline of the product thats really not changed, it just reordered.\\nRaj Denhoy ',\n",
       "   'answer': ''},\n",
       "  {'question': 'Okay. And then, sorry, just last one, just on gross margins, you mentioned low 60% for the U.S. How much more is left there? I think you have talked about kind of getting into the low 60s with the Gen2 where the current generation pod, how much left do you think there is in driving that gross margin higher?',\n",
       "   'answer': 'Personally I think theres a lot of that. I mean, I think that there is  Im sure at some point theres a theoretical feeling, but I said to different people at different times. I certainly Im not willing to  you put us feeling on our ability to gain leverage in the business. I mean, we should be able to continue to drive as the business gets bigger and bigger and we add more lines, more and more efficiencies that should be able to drive the cost of different components done and be able to spread out the overhead even more. And so, I think as we looked at this quarter, we gained a couple hundred basis points on the U.S. OmniPod basis. We lost a little bit on our consolidated margin when you look at international share in the neighborhood mix. I think when we look at Q4 to gain a couple of hundred points more of margin, its absolutely achievable. And hopefully all of that close to the consolidated, but again, that will just depend a little bit upon mix of the different components of the business.\\nRaj Denhoy '},\n",
       "  {'question': 'Thats helpful, and you will be miss,',\n",
       "   'answer': 'Thanks, Raj.\\nBen Andrew -'},\n",
       "  {'question': 'Good afternoon. And Ill add my congratulations and also to everybody thats staying with the company, and Brian, we will miss you. Two questions I guess from me, first, can you talk a little bit about the new patient add trajectory in Q3 and whats implied in Q4, was it plus minus 20% or whatever detail you can give us there. And then, whats the neighborhood diabetes revenue number for the quarter or maybe a percentage there if we can?',\n",
       "   'answer': 'Yes, sure, Ben, its Brian. So a couple of things in new patients starts, I think as Pat mentioned in his remarks I think were seeing some nice productivity uptick for the new territories where weve added the provable third man in form of kind of this KAM or territory associate kind of role. Overall, we saw probably somewhere about 5% to 10% sequential increase in new patient starts from Q2 to Q3. Still on the trajectory I would tell you a kind of somewhere in the 15% to 20% range overall, new patients starts year-over-year and the trajectory still seems very solid here as where month and few days into the fourth quarter. So I think everybody is feeling good about that and obviously the payer issue kind of being put to bed. I think allows everybody to feel that much more confident as we end this year and look forward into 2015. On the neighborhood side, neighborhood, obviously we lapse competitive bidding this year in the third quarter that was July 1 of 2013 when CMS kind of really significantly reduced the pricing of blood glucose testing supplies. The neighborhood business was up slightly in Q3 on year-over-year basis, probably a couple percentage points. Again, absolutely kind of filling their role and doing a good job, only difference as we have seen in settling a gross margin basis has come down a little bit as the mix of the business has changed and obviously the lower pricing overall from blood glucose testing strips.\\nBen Andrew -'},\n",
       "  {'question': 'Okay. And then Pat maybe a question for you that I think weve all kind of looked at over the years, why is  given that only 30% of people are using insulin pumps there is obviously reasons for that. What do you think is the bottlenecks to adoption that Insulet can address them here that perhaps it wasnt addressing effectively before and what are the real levers that you guys can bring operationally to try to accelerate that?',\n",
       "   'answer': ''},\n",
       "  {'question': 'I think there is a number of atleast my initial read on the whole insulin market are Type 1 diabetes market. You have certainly those that are in the multiple daily injections and mostly patients start out in that therapy and then move over to being considered for pump and pump therapy. And I think as weve done market research into the market, it appears that there is a large number of MDI patients that would never consider a pump if they had to use the current conventional pumps, but when provided with the opportunity to use OmniPod the uptake or the interest level is exceedingly high. So I would say what we need to do is focus on the marketing message through the endocrinologists and getting more MDI patients converted to the OmniPod technology. So I think from my perspective, its really leveraging the -- sales force presence in the field and focusing on those high prescribers. And as I said earlier if you look at the number of patients below 18 this is where the product really I think is very good for the kids and their parents to manage these patients with type-1 diabetes. So focusing on that market segment I think will pay great dividends.\\nBen Andrew -',\n",
       "   'answer': ''},\n",
       "  {'question': 'Were the things the company wasnt doing effectively before from that marketing message to end those or is this just simply going to require a fair bit more of spending whether at times sales people or marketing dollars to accomplish.',\n",
       "   'answer': ''},\n",
       "  {'question': 'Well I think its fair to say that in order to grow were going to have to add sales and marketing resources to get the message out and to have adequate coverage in the market place. When I compare sort of what we spent at Cytyc at the same level of $300 million in revenue versus where we are today, at',\n",
       "   'answer': ''},\n",
       "  {'question': 'Im not prepared to give you exactly what that looks like today because Im still more struggling to do that process, but I think its fair to say that were going to add additional sales from marketing resources.\\nBen Andrew -',\n",
       "   'answer': ''},\n",
       "  {'question': 'Great. Thank you.\\nWilliam J. Plovanic  Canaccord Genuity,',\n",
       "   'answer': ''},\n",
       "  {'question': 'Thanks, good evening.', 'answer': ''},\n",
       "  {'question': 'Hey Bill, how are you?\\nWilliam J. Plovanic  Canaccord Genuity,',\n",
       "   'answer': ''},\n",
       "  {'question': 'Good. So Im on the airport side theres some background noise. You know saying welcome Pat, congrats to Allison and Brian definitely missed. Most of my questions have been asked but this time Im going to ask more pointed questions. Just it sounds you are kind of still viewing things that sounds like but as we think about 2015 and the current revenue expectations and even profitability expectations out there, I mean should we  can we [casually] say you are comfortable with that, it sounds like maybe from an operating standpoint maybe some more investments in sales and marketing, I know you are still 50 days in getting in there, but how should we start thinking about as you put your stamp on the business from 2015 and beyond?',\n",
       "   'answer': 'Hey Bill, its Brian. Let me take a first crack at some of it and I think were prepared certainly the company as we get into the first quarter will ultimately provide appropriate guidance for 15 but I think there is a couple of takeaways. One is, weve been adding sales resources as we know and kind of these 20 person or so kind of chunks, because it works well from a historically from a manufacturing side for not over taxing the sales management and the infrastructure of the business the reimbursement pieces and the like. And that has worked really well and so again I think one of the things to take away is this kind of again third man in or so that we have put into some of these territories, assuming that although early days keep in mind these folks have only been in the field now for one full quarter. They seem to have some good momentum and productivity behind them that I think is something that the team it works through strategic planning and budgeting here in Q4. Its really trying to figure out how that model works and do we add more  there are certain territory level where it doesnt isnt as effective and really kind of what that planning is. And a lot of the marketing type things you will recall six months ago or so we talked about we hired for the first time an agency of record and digitized to able to come in here and help drive the branding and help I think really push messaging into the healthcare professional community, that talks about pumps make sense for multiple daily injectors, we need to move them on the pumps and this is how you do it. And I think all of that stuff is resonating and as for me one of the things that I shared with Pat when he started was a call -- this in my mind is a really great time for him to kind and join because in a lot of ways its the first chance that this business has had in a long time to play off and its versus [Indiscernible] as you guys know from following this company for a long time we were worried about how running made its action capacity with the old part and now Im going to try to work at getting then new part approved and then the transition of the customer base which took up a big chunk of last year and then this year now we are putting in those building blocks into place. And I think if anything some of the momentum of whats been invested here over the last six to nine months is starting to show some of those dividends. And so I think thats a really exciting thing to be. You know that said, and Bill I think Pat as he kind of keeps that in kind of starts to allude to it, there are absolutely things we can do better. And I think his leadership and his commercial experience and what hes been through along with Pete [Douglin] and his team and the planning effort they are will drive a lot of what makes some of those new investments look like next year.'},\n",
       "  {'question': 'Yes I think what Brian just discussed and I would also say that Ive spend the majority of my time over the last 50 days being mostly internally focused inside the understanding, manufacturing R&D and then our commercial efforts, but now Im turning my attention to spending more time in the field with the field force and over the next couple of months getting a good flavor of how we execute the sales strategy in the field and would come back here early next year with my assessments and plans for 2015.\\nWilliam J. Plovanic  Canaccord Genuity,',\n",
       "   'answer': ''},\n",
       "  {'question': 'Fair enough thank you. And then some -- questions, just on the I was wondering with the Amgen can you quantify what you believe that market opportunity is and when do we actually start seeing that show up in the business?',\n",
       "   'answer': ''},\n",
       "  {'question': 'Well Neulasta for Amgen is about $4 billion product in the United States. There are I think as Ive done the research about 900,000 patients are used at right every year and it currently in its current form is approved by the FDA. This filing is for use of that product and our OmniPod. I would say it we will assuming it gets approved in the fourth quarter or early next year we expect to receive revenue from it, but its hard to really put a number on the table because it all depends upon how that launch goes for Amgen but I know that they are extremely excited about and we are working very hard with them for a very successful launch.\\nWilliam J. Plovanic  Canaccord Genuity,',\n",
       "   'answer': ''},\n",
       "  {'question': '', 'answer': ''},\n",
       "  {'question': 'We expect to show that PDM at the ADA Meeting in the next summer in Boston, so we are going to have a coming out party in our home town with that product and would expect to file that in early 2016.\\nWilliam J. Plovanic  Canaccord Genuity,',\n",
       "   'answer': ''},\n",
       "  {'question': 'But you will show that ADA but you will file the PMA  Im sorry the 510(k) in early 2016?',\n",
       "   'answer': ''},\n",
       "  {'question': 'Correct.\\nWilliam J. Plovanic  Canaccord Genuity,',\n",
       "   'answer': ''},\n",
       "  {'question': 'Okay, great. I think thats all', 'answer': ''},\n",
       "  {'question': 'Safe travel, Bill.\\nWilliam J. Plovanic  Canaccord Genuity,',\n",
       "   'answer': ''},\n",
       "  {'question': '',\n",
       "   'answer': 'Yes, thats correct. Because again each passing quarter you have to include the reorders or the last reorders if you will for the patients that didnt start the quarter before. So yes my assumption really hasnt changed from what we talked about back last quarter whether which was those about a million and a half of it impacting Q2 probably somewhere in the 3 to 3.5 million range in Q3 and then probably 4 5 or so in Q4 is we start to see the new patient start kind of pipeline ramp up again. No different metrics, right. So 5% to 10% sequential growth Q2 to Q3 when we talked about 20% we are talking year-over-year, right. And the year-over-year we talked about that full kind of nine month period, so on a year-to-date basis which is that so, just to make sure we dont mix and add there. I mean I dont want to comment about actual patient count numbers, Ill just leave it to say that were about 5% to 10% higher sequentially in Q3 than we were in Q2. I dont have all the models in front of me.'},\n",
       "  {'question': 'I think conceptually we are looking at the market place and basically looking at the drugs that are currently on the market and the opportunity for using the OmniPod as a special drug delivery device for those products whether they are currently on the market or in development, in stack ranking those in terms of opportunity and near term sales growth that we could expect from those type of applications and then putting resources against those opportunities to really capitalize on this use of the OmniPod. I mean, I think from  you can leverage two things. You can leverage the technology which this obviously does and focusing on new sales and marketing to leverage the sales force. So were going to definitely making plans to leverage this technology.',\n",
       "   'answer': 'Its interesting when you think about like one of the benefits of the product when you think about existing drugs is looking at when certain compounds or things come off a patent for example could be an interesting way, the interesting reason why adding in a delivery device like the OmniPod makes sense. And we keep in mind that, that with a lot of these and even with the Amgen product weve seen it, it takes a few years once from when you sign a deal its ultimately be able to get it to market, because of the process of either maybe a little bit of development, maybe not but then ultimately going through the obviously the FDA process. So Capricor is on the other side that which is  there is the phase 2 product and we are helping them through their clinical trials. Now the reality of when that becomes a commercial product years down the line, but its exciting to be part of that one too and really affect to be part of their filing. So theres a mix of them in the pipeline, Ferring is obviously an approved one in Europe and we have been generating revenue from it. Amgen will be next and then as we continue to add more and more of these projects and we have a couple more on going, well see how those develop and above and be able to drive actual timelines for each one. Just we have about 135 people or so in the field. Right now I think we are still split at 53 territories, right. So that would basically  so 53'},\n",
       "  {'question': 'Okay, great.', 'answer': ''},\n",
       "  {'question': 'Hey [Tow].',\n",
       "   'answer': 'Apologize, Im not sure I completely follow that, but were  again, where were heading just and so we stay clear here is on a year-over-year basis weve talked that were looking effectively for 20% year-over-year patient growth, new patients starts and I think everything has been trending close to that number. Were probably little lower than that at the moment, but again if you look at specific issue around the payer thats been one thats been driving it. On a quarter-over-quarter basis, Q2 to Q3, I mentioned a couple of minutes ago that were basically driving between kind of 5% and 10% sequential growth. So those are the two pieces. In regards to the payer issue specifically its an open question, right, because what you seeing with the patients are in some cases they may  if there a chronologist is been saying, look you need to give on pump and unfortunately we cant get this when approved right now, but you got to get another pump, some of those patients may have gone elsewhere. Some may delay their decision. Some wait for the next trip back to the doctor. So, theres our team has done a really good job I think in the commercial side of trying to keep the patients  the pipeline warm if you will and trying to be able to bring these folks openly across the goal line. No one that were able to get this result, but ultimately we have to see how that plays itself out. So, from that perspective I dont think theres any difference. I think when you look at the revenue growth in the business, again, weve always been a midpoint company and when we updated guidance last quarter, the midpoint of that range is 295. If you look at the midpoint of the range that we gave you today is 295. So I dont think theres any real change or difference there at all. I mean, thats overall pipeline, right, so were not talking about just one pair here. Were talking about the overall pipeline and that is absolutely not changed. I mean, the team is continues to do a good job of drive-in referrals and ultimately those referrals turning into new patients starts. So, I think weve seen good momentum in that business overall. My only comment specifically to this one pair is its unclear for patient who is looking start on OmniPod back in May is going to still be there for us to be able to convert in January. I mean, were certainly try, right, but its a little less clear to be to say everybody is willing to wait six, seven, eight months or whatever it is to be able to finally cross the goal line.'},\n",
       "  {'question': 'Okay, great. Thank you.\\nMike Rich ', 'answer': ''},\n",
       "  {'question': 'Hi. This is Mike Rich calling for Jayson. Can you hear me, okay?',\n",
       "   'answer': 'How are you?\\nMike Rich '},\n",
       "  {'question': 'Hey, guys. Thanks for taking the questions. Most of my questions have been answered. But I just wanted to circle back to a couple of things. First, good color on the partnership with Ypsomed outside of the U.S. I know youre tracking for doubling growth this year, but can you comment on the sales growth outside the U.S. in the quarter or perhaps what percent of sales, international sales were?',\n",
       "   'answer': 'Not at this point I guess, but as Ypsomed said last week, I mean, theyve seen over their last six months about a 60% or so increase in their business. Were absolutely on track when we look at our international partnerships which will also include GlaxoSmithKline for Canada, to double our international revenue in 2014 versus 2013. And as Pat in his remarks, I think were really excited and hopeful that were going to see reimbursement in France very soon, and France is a really interesting market in Europe. I think its the second largest pump market in Europe, and today we sit with the zero there. So, getting France over the goal line would allow really another really good growth opportunity Ypsomed as they turn the corner into calendar year 2015. But overall, I think the international business has been doing great again. One thing you can point a little  the revenue share is great. There are certainly helping us to drive to net breakeven at the operating level or an operating profit. Its lowers the gross margins slightly, but thats a good trade off.\\nMike Rich '},\n",
       "  {'question': 'Got it. Okay. And then is there timeline for OmniPod approval in China?',\n",
       "   'answer': 'Not anything at this point. I mean, I would tell you that weve continued to kind of work through the regulatory process over there in China. I dont have an update on it. I know that were still need [Ethernet] but its probably some while the companys feeling we get.\\nMike Rich '},\n",
       "  {'question': 'Okay. And then lastly sorry, I missed this, but an update on the currently generation like PDM with LifeScan meter?',\n",
       "   'answer': 'Yes. Were looking to hopefully have approval that. Very soon weve responded to all of the FDAs questions. Most of the questions that the agency came back with actually were more I would say a LifeScan driven and Insulet driven and well see some questions around the various strip and those pieces which our partner has done a great job of responding to and providing the data for. So, were just in the waiting game at the moment. But hopefully well have an answer pretty soon.\\nMike Rich '},\n",
       "  {'question': 'Okay. Great. Thank you very much.\\nJan Wald -', 'answer': ''},\n",
       "  {'question': 'Thank you. And congratulations to Allison, Brian and Pat welcome and good luck. I guess most of my questions has been answered, but let me just ask a couple of more. Maybe taking also on [Dave] question a little bit more on profitability versus investment. Not looking for whats youre going to do, but how do say company moving forward. You company at your stage looks towards profitability but it needs to make investments. How do you see the priority of those two things occurring over the next year to two years?',\n",
       "   'answer': 'One of the nice things Jan, weve able to find a good balance to both of those in the past, as you could see from the fact that weve been able to balance I think a very strong overall top line growth with getting now operating profitability, $4 million of operating profit excluding up the transition costs is are highest level of operating profit and obviously we continue to feel very bullish about pushing more gross margin to the business. So, I think the business has positioned well to be able to find balance for both those going forward, which is a good spot for the company to be.\\nJan Wald -'},\n",
       "  {'question': 'Okay. I guess my next question is in your prepared remarks you mentioned there are more efficiencies that youre going to look for. I think you probably meant to manufacturing? What kinds of things would you be looking to do in manufacturing with us, I guess elsewhere in the business can might improve those  might lead to more efficiencies?',\n",
       "   'answer': 'Specifically when we talked about, we have the fourth manufacturing line come up and one of the thing that been interesting in our manufacturing processes, with each line were obviously getting smarter of how to make an OmniPod with highest level of quality and most cost effectively possible. And so I think Ive shared in the past that when you look at Line 3 for example, right now its been our efficient line and weve been able to make some small adjustments for like Line 2 for example to make it look Line 3, so that one becomes the lot more efficient. Line 1 for us is probably been  always been our most inefficient line where its highest level of people required and with the lowest capacity. So when Line 4 comes on board for example, its going to mere image Line 3, so well get that efficiency out of the gate and it starts to give us some flexibility to think about how we can better leverage Line 1 for example and therefore spread out overhead cost and look at the amount of direct labor required and those type of things hopefully further bring down the pod price. That plus as we keep moving up the volume spectrum, were able to drive some additional cost components increases from our suppliers, which is also another positive and helping us generate more gross margin. So, those are couple of examples that where more efficiency can be gain.\\nJan Wald -'},\n",
       "  {'question': 'Okay. And my last question, on the CGM center, it sounds as if youre still going through some kind of design process, because youre addressing the kinds of issues that would get addressed in design. Any sense of when youre going to be  when it will design for use or some like can you be able move into the clinical?',\n",
       "   'answer': 'I think weve said, that we said, weve been going to a process obviously the sterilization weve gone through this latest testing we did was earlier on this idea of distance between sensing and dispensing and we think  we got some  we believe some pretty favorable results out of that. So youre right, that is still kind of a design phase if you will. And weve talked about doing some inhuman trial work hopefully sometime early to mid 2015. Ultimately well see where that timeline is driving towards in the second kind of all the [indiscernible] next real indicator to drive the overall timeline of the project. So as we get closer to that point, that probably the next checking time.\\nJan Wald -'},\n",
       "  {'question': '', 'answer': ''},\n",
       "  {'question': '', 'answer': ''}]}"
      ]
     },
     "execution_count": 113,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "process_single_transcript(transcript2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "540c1a3d",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "05f96e32",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "faa2d169",
   "metadata": {
    "scrolled": false
   },
   "outputs": [],
   "source": [
    "def remove_operator_lines(transcript):\n",
    "    \"\"\"\n",
    "    Removes all lines that start with 'Operator:' \n",
    "    (assuming each Operator statement is on a single line).\n",
    "    \"\"\"\n",
    "    # ^Operator:   => line begins with 'Operator:'\n",
    "    # .*          => then remove everything else on that line\n",
    "    # (?:\\n|$)    => include the line break or the end of string\n",
    "    cleaned_transcript = re.sub(r\"^Operator:.*(?:\\n|$)\", \"\", transcript, flags=re.MULTILINE)\n",
    "    return cleaned_transcript\n",
    "\n",
    "\n",
    "# remove_operator_lines(after_second_operator)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "def5d570",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Questions:\n",
      "- I guess, my question is a bit more technical in nature, but if I look at the $207 million of total investment income in the third quarter, can you let us know how much of that was from KFN, just trying to get a sense of how that stacks up against the $53 million of net realized investment income from KFN for the quarter. And then, stepping back, how do you see that ratio holding going forward? I think, in the second quarter it was something like 2/3 of\n",
      "- You guys are probably as sophisticated as any in valuing businesses. And I'm curious as to how you value your business and at what price or point would it make sense for you to take some of that, I guess, it's $11.5 billion of cash investments on your balance sheet, which is about 65% of your market cap, to basically buy back your own shares, if you thought they were misvalued or do you think they misvalued?\n",
      "- Just 2 things. One is the -- in the Public Markets, the unrealized investment losses, the $46 million that we see, is that primarily the mark-to-market on the CLOs and KFN, because you could see that they were marked prior -- slightly above cost in the second quarter and slightly below in the third?\n",
      "- Okay. And then just a kind of bigger picture. In the recent weeks, there were 3 kind of un-KKR like investments, smaller, more ventured capital kind of investments, Magic Leap, Lemon Restaurants, Ping Identity and things that I don't think have been down the center of the fairway for KKR. And can you discuss that strategy and where they fit in the grand scheme of things?\n",
      "- You talked a lot about the growth in your strategies that are moving into their second generation of funds. Can you give us an update on where each of those stand in terms of either raising that second generation or starting to raise that second generation?\n",
      "- Scott, can you just address the environment in terms of what you might expect from strategic versus ECM exit outlook? I'm particularly curious how the recent volatility might play into maybe the mix of exits there?\n",
      "- Scott, I appreciate the forward comments on the deployment opportunities. Maybe if you could just go into a little bit more detail, obviously, seeing a little bit of a rebound in the markets here, but if you could talk a little bit about how aggressive you think you might be on deploying capital and then elaborate over the next, say, 1 to 2 quarters and then in 2015. And then also a little bit more detail on the -- on some of the energy opportunities that you touched on.\n",
      "- So quick one on the exits. Bill, you talked about First Data, U.S. Foods and Biomet kind of in the queue. Curious if you guys expect those to close in the fourth quarter, and then if maybe you can help us out with kind of a range of potential dividends that you would expect from those exits?\n",
      "- I just want to follow-up on my question about the CLO marks. Just -- some of the pushback I get on the story is around perceived credit risk from taking on the KFN portfolio. Just wanted to make sure that, the marks that are occurring are purely market driven and there isn't any sort of credit deterioration going on in this portfolio.\n",
      "- I guess I got back in the queue pretty quick. Scott, thanks for your comments about Energy, that's very helpful. Just had another question about an area that seems to be slowing down and that's China and Asia. Are you guys seeing any stress at all in your portfolio of companies, as a result of things slowing down there -- I mean, it appears no, but just any comments you can give us there would be great.\n",
      "- Appreciate the color on the capital deployment. Just a follow-up, I guess, on that topic. Maybe more on the private side, but clearly, you guys want to put money to work when there is dislocations in the markets, but it hasn't been your experience that in volatile times it becomes harder to actually to get money deployed or to lock down terms just when prices have significant fluctuations? Just curious if -- clearly, you want to get the money into the market, but does it actually become harder to do when the markets are volatile?\n",
      "- I don't know if this is an appropriate question, but you guys put a significant amount of additional capital into First Data, and\n",
      "- Scott, maybe just on some of the investments that are going into Europe. When you think about sort of the backdrop there and who knows how it plays out, but if the growth is on the slower side, how do you guys think about what you want to pay in terms of the valuation currently, when you're modeling the outlook, what the economic growth assumptions are? And then if it does slow, what can the portfolio companies do to offset it, meaning there are more on the cost side, are there revenue synergies? How do you guys think about that, because there is somewhat of a level of uncertainty in the region?\n",
      "\n",
      "Responses:\n",
      "- Thanks, Stephanie. We -- looks like we have actually a sizable number of people in the queue. So if you could please limit yourself to one initial question and then rejoin the queue if necessary, we'd appreciate it.\n",
      "- Hi Michael, this is Bill. Thanks for the question. As it relates to KFN, you are right in that we do provide some realized information and so in the second quarter we showed in the distribution that $36 million came from KFN and in the third quarter that's $53 million, so roughly about $89 million year-to-date. On a run rate basis, that's a realized return of about 9%. When you take into account unrealized returns, which is embedded in that $207 million, KFN right now is performing much better than we had expected. That being said, KFN is a little complicated because when we closed the transaction, some of the assets were Public Market investments, CLOs, et cetera, while others were Private Market investments, which would have been Real Estate and Energy. The way we look at it is we look at this more holistically because we put all of the results from KFN and KKR proper's balance sheet together, but the bottom line is, from a modeling perspective, the realized income is on pace or a little higher than we had expected and\n",
      "- Our next question comes from Lee Cooperman with Omega Advisors.\n",
      "Leon G. Cooperman - Omega Advisors,\n",
      "- Thanks, Lee. Appreciate the kind comment. This is Scott. I think it's a great question. I think, today, the markets have been -- they are working to figure out how to value our business and other businesses that are somewhat like ours. In terms of how we've thought about it to date, Lee, what we've really been looking at is valuing ourselves the same way that we value companies that we invest in. We like cash flow and we look at the return on capital and the return on equity, overall. And as we've talked to our shareholders about how we think they should think about us, we have emphasized those metrics. Our perspective has been that you can't eat AUM, you can spend cash flow. And so we have been focused on making sure we're driving the total cash flow up and we took you through the numbers, you can see total distributable earnings up 75-plus percent year-to-date. So we're making progress. So far, what we've determined to do is to share that cash flow back with our investors through a high payout ratio. And year-to-date, that's been on the order of 76% of the cash flow we've paid out in the distribution, which has been also increasing rather significantly. When we looked at how to take these trade-offs views before, what we've looked at is year-to-date and over the last few years, our ROE has been 25-plus percent. And so, when we've looked at opportunities to invest capital internally versus buying shares back, we've kind of put it all in the mixer and said, \"All right, we can deploy our capital against opportunities we have and generate 25-plus percent returns on that capital,\" that's a pretty good return. So while we think our stock does not properly reflect the cash flow we generate, we found attractive ways to deploy capital internally and have been to date returning capital to shareholders through a very high payout ratio and a very high dividend. I think you're asking a good question. Is that the right approach for the long-term? And the answer is this is the approach we've taken so far, but we'll continue to look at it.\n",
      "- That's absolutely right, Chris.\n",
      "Christoph M. Kotowski - Oppenheimer & Co. Inc.,\n",
      "- Yes, Chris, happy to. This is Scott. Look, I think, we have found across a number of the different industries that we spend time in, Chris, that periodically we've run across interesting smaller investment opportunities that are more growth equity in nature. Historically, we have passed on those because it didn't fit into a private equity mandate or any of the other strategies that we manage, but we've found many of them to be quite interesting. And so there are some sectors. Technology, retail, healthcare have been those most active. We're now with our balance sheet, we've taken the view that we can actually make some of those investments, which we're doing on balance sheet today. We'll see how this strategy evolves. As you recall, with our Real Estate strategy, that started as an on-balance sheet strategy that we dropped into a fund. We may do that with growth equity down the line and we may not, but think of these as opportunities sourced by our investment teams that historically we passed on and now we have a way to monetize.\n",
      "- Sure, Patrick. So let me just run through a number of different strategies because this also feeds well into kind of what we're doing from a fundraising standpoint in the market. But if you kind of go around the world and across the different businesses, as you know, we recently raised our Asia II Fund for private equity. So that was our private equity successor fund that was about $6 billion. We have a number of Fund II strategies that we're actually in market with now or will be shortly, including infrastructure, our direct lending platform, where we're raising fund to special situations, which is also in the market with Fund II mezzanine II or a private credit II, is also a strategy that we're going to be raising here shortly. So a number of different strategies that we're in the market with Fund II right now. And then, there's others that you'll see coming, including Real Estate. So as you kind of go across all the different strategies, and I think there is 7 or 8 different vehicles that we've built, where we had\n",
      "- Our next question comes from Marc Irizarry from Goldman Sachs.\n",
      "Marc S. Irizarry - Goldman Sachs Group Inc.,\n",
      "- Great, happy to, Marc. Look, I think, if you look year-to-date, it's interesting. We've talked about this a lot over the course of last couple of years, that we've been seeing more and more of our exit activity, actually come from strategic exits or dividend recaps, et cetera. And if you look at what's happened year-to-date -- if you look at what's actually closed, secondaries have been about 40% of the cash that we've returned, with strategic and dividend recaps making up the other 60% or so. But if you actually kind of pro forma for a bunch of the strategic sales that we've had, remember, we've had 8 or so strategic sales announced over the course of this year. If you go back to Oriental Breweries, Sunrise, Avincis, Alliance Boots to Walgreens, Biomet, U.S. Food, Wild, Versatel. We've had a lot of strategic sales announced this year and if -- you've got 5 strategic exits, couple of which are now closed, but 3 of which are still pending. If you kind of pro forma the value that we've returned to investors, as a result of all of that, you see about 80% of that is strategic sales or dividend recaps, and only 20% or so is actually from the equity capital markets. So we have a lot of optionality as to how we exit investments and are not dependent on the Public Markets per se. So what's been pleasing for us as we thought the strategic buyers would come back and we are starting to see that come through. And as I said, it's now that and the leverage credit markets are 80-plus percent of what we're returning.\n",
      "- Our next question comes from Brian Bedell with Deutsche Bank.\n",
      "Brian Bedell - Deutsche Bank AG,\n",
      "- Sure. Happy to, Brian. Look, I'd say, in terms of deployment, I think, it's important to keep in mind, we're a very global business, okay? So probably half -- over half of our investment teams are outside the United States and as I mentioned, we've actually been very active, in particular, over the course of last couple of quarters in Asia and Europe. And as valuations we felt were a bit high in the U.S, we pulled back a bit, especially in private equity in the U.S. But in terms of what we're seeing right now, I'd say -- let me start with Asia, active. We deployed year-to-date nearly $2 billion in private equity. We've done our second deal in Japan this year. And so we're starting to see that market open up a bit. We bought a stake in a public company in China called Haier. It's somewhere between 3 and 4x EBITDA, as that market was dislocating a little bit, so we were able to take advantage of that. But also if you look across Asia, we've been busy in special situations. And in Real Estate, and -- so we're finding a lot of different opportunities in Asia and are particularly upbeat about the special situations and kind of a rescue opportunity in that market. So I'd say, let's start there. I'd say -- I'd expect us to be quite active on the deployment front as those Capital Markets continue to develop and it's both kind of special assist, direct lending and the other areas that I mentioned. Then I'd go to Europe, the liquid markets had really started to run a bit in Europe. We've seen a bit of a pullback. We did our first deal in Africa this year, so our MENA [ph] strategy is continuing to develop, but we're also continuing to see opportunities in private credit. Special situations, direct lending, we have actually used all the capacity we have in our Real Estate Fund for European investments, so we're going to be launching a Real Estate Europe strategy as a consequence of that, and we've been expanding. We opened an office in Madrid. We're adding talent and we think direct lending type strategies are a great opportunity in Europe. So where there is dislocation, I think, you will continue to see us being very active on the deployment front. In the U.S., as I mentioned, we've been a little bit more cautious as of late, probably, more sellers than buyers in private equity, but we've continue to deploy capital in special situations, direct lending, Real Estate and Energy. So overall, where there is a little bit of fear, we get excited and find opportunity and when valuations are a bit elevated, we have a big portfolio and the opportunity to access the markets. And so, we actually are pleased with the current environment. I think we'll find things to do. In terms of your question around Energy, in particular, look, as I mentioned, we've been pretty quiet in Energy private equity for a long while because valuations had gone up so much. There's some sectors in the Energy market that have traded off in the public markets, 30% to 50%. And that will create opportunities for us, hopefully, going forward. And we're continuing to stay busy in infrastructure, energy-related and otherwise, and also in our drilling and royalty strategies, which are more private market strategies. So this is a little bit of color for you, but it's active.\n",
      "- Chris, this is Bill. With regard to the 3 that you mentioned, so I'll take them one by one. U.S. Food, we still haven't gotten clearance yet. We were cautiously optimistic that, that might close in the fourth quarter, but it could actually slip until the first quarter. As far as Biomet is concerned, we're hoping that's going to close in January of 2015, and so that will be a first quarter event. And lastly, on Boots, we're expecting that to take place in the first quarter of '15 as well. As far as giving any guidance on what the cash distribution would be, it's a little complicated and we'd much rather not give that type of guidance because each one of those transactions is part cash and part stock.\n",
      "- Yes. And Patrick, this is Bill. You're absolutely right. The portfolios are performing fine, but when you have disruption in a credit market on a mark-to-market basis, the CLOs might be marked down, but the underlying performance is still there and nothing that we're worried about right now.\n",
      "- And I'd say critically, Patrick, the cash flow coming off the\n",
      "- Which is why the results for KFN so far, both in the second quarter for the 2 months and the full third quarter, have been a little better than we actually expected.\n",
      "- No. Chris, we really haven't seen a slowdown that's noticeable. In fact, our revenue and EBITDA growth in our China portfolio has been good and our overall Asia portfolio has been very good. So remember, we're focused on investing in private companies in China that have exposure to the consumer and so some of what you are seeing in the Public Markets has been disconnected from what we're experiencing in our private companies. So, so far so good on the overall portfolio in Asia, in particular.\n",
      "- Our next question comes from Devin Ryan with JMP Securities.\n",
      "Devin P. Ryan - JMP Securities LLC,\n",
      "- That's a great question, Devin. So the answer is it depends on how much volatility there is and it depends on the asset class. So if it is extremely volatile and a lot of distress, then private equity, the buys are very attractive when you can make them, but only a few transactions happen if there is extreme distress, because you don't sell unless you absolutely have to, and there's not a lot of those opportunities out there. But where you've got, what we've seen so far, which is this kind of asynchronous recovery, where you've got bumps in the road from time to time, we have actually continued to see deal flow in that environment because it's not such a severe dislocation. So this has been the kind of dislocation where we're continuing to find opportunities as opposed to the market shutting down. But when you go to the other end of the spectrum, you go to our liquid businesses, market dislocation is a very attractive buying opportunity as long as the markets remain somewhat liquid, when their price deterioration and a lot of participants in those markets have short-term capital and we have long-term capital. And in the case of the balance sheet in some of the vehicles that we manage, we actually have permanent capital. So we can take advantage of those dislocations on the liquid side, and that's actually a market where we find that we can make some great buys, if the high-yield market, as an example, pulls back and becomes more attractive. And then, you've got strategies that are in between. Think private credits, special situations, mezzanine, where if companies cannot access capital because of dislocation or a change in behavior from traditional lending institutions, that's a great environment for us. So that's why this environment we've seen over the last few years of overlying kind of improving economic fundamentals, but these periodic periods of volatility are allowing us to be active across a number of our strategies and deploying capital into what we think are some pretty interesting risk/reward opportunities.\n",
      "- Lee, it's Scott. I think, what we'll probably do on that one, Lee, is leave it to the First Data management to talk about on their earnings call. But you're right, we did deploy significant incremental capital into that company as our largest investment, and I think it's fairly straightforward from our standpoint, we're big believers in the management team and the strategy and we wanted to have more exposure.\n",
      "- Our next question comes from Mike Carrier with Bank of America, Merrill Lynch.\n",
      "Michael Carrier - BofA Merrill Lynch,\n",
      "- Look, I think it's a great question. But we have -- we started with the perspective that Europe is not a monolith, right? So you've got a variety of different views depending on the market. So we're finding the peripheries doing a bit better, Ireland and the U.K. are doing well; France, Netherlands, Italy, slightly better than they were, but still weak; Germany pulling back a bit. So you look at the underlying fundamentals of that company and the markets that they're exposed to. And then what we've done is we've created in the middle of the firm, a global macro and asset allocation group that's working with the teams, so we have a view on how each of those underlining economies may perform over the course of our investment horizon. And then, we layer onto that, that we have very long-dated capital. And so we're fortunate that we are in the long-dated option business so that we can create the option when we want and we can choose to exercise the option when we think it's appropriate. So we'll have a view as to when the markets may recover, but we have several years for that to happen. So it's really the way we look at it is to say what is the right way to capitalize this enterprise once we have a view as to that growth profile, given that underlying backdrop? And what we're doing is we're capitalizing these companies conservatively from debt -- capital structure standpoint and really making sure that we've got leverage to pull, operationally. The best run companies with the best management team in the industry and the highest margins, the returns probably aren't going to be there. So you need to have operational skills to actually invest in companies that you can make better. And so you kind of mix all that together and develop a model as to what you think can happen over the long term, and then we've got to make sure, even after you do all that, that we're compensated appropriately from a reward standpoint for the risk we're taking. And that analysis we do for private equity, but we also do it across our special situations platform, where we're creating some equity upside and a lot of the investments we're making, and even in direct lending type strategies, where we are more in the secure part of the capital structure, you have to think about the downside. And so -- I mean, that gives you bit of a sense for how we approach it, but it's very much market-based grounds up.\n",
      "- Thanks, again, Stephanie. And thank you, everyone, for your interest. Happy to follow-up directly with any other questions that you might have.\n"
     ]
    }
   ],
   "source": [
    "# def categorize_transcript_without_operator(transcript, executives, analysts):\n",
    "#     # Remove all sections where the speaker is \"Operator:\"\n",
    "# #     transcript_without_operator = re.sub(r\"Operator:.*?(?=(\\n[A-Z][a-zA-Z\\s.']+:)|$)\", \"\", transcript, flags=re.DOTALL)\n",
    "# #     transcript = remove_operator_lines(transcript)\n",
    "#     # Create lists to store questions and responses\n",
    "#     questions = []\n",
    "#     responses = []  \n",
    "\n",
    "#     # Split the transcript into individual speaker sections using regex\n",
    "#     sections = re.split(r\"(?<!\\w)([A-Z][a-zA-Z\\s.']+):\", transcript)\n",
    "\n",
    "#     # Ensure valid splitting\n",
    "#     if len(sections) < 3:\n",
    "#         return questions, responses  # Return empty lists if no sections found\n",
    "\n",
    "#     # Iterate through sections to identify speakers and their dialogues\n",
    "#     for i in range(1, len(sections) - 1, 2):  # Step by 2 (speakers and dialogues are paired)\n",
    "#         speaker = sections[i].strip()\n",
    "#         dialogue = sections[i + 1].strip()\n",
    "\n",
    "#         # Check if the speaker is in the executives or analysts strings\n",
    "#         if any(name in executives for name in speaker.split()):\n",
    "#             responses.append(dialogue)\n",
    "#         elif any(name in analysts for name in speaker.split()):\n",
    "#             questions.append(dialogue)\n",
    "\n",
    "#     return questions, responses\n",
    "\n",
    "\n",
    "# questions, responses = categorize_transcript_without_operator(after_second_operator, executives, analysts)\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "# # Print results\n",
    "# print(\"Questions:\")\n",
    "# for q in questions:\n",
    "#     print(f\"- {q}\")\n",
    "    \n",
    "\n",
    "\n",
    "# print(\"\\nResponses:\")\n",
    "# for r in responses:\n",
    "#     print(f\"- {r}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "8e92892d",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Q1: I guess, my question is a bit more technical in nature, but if I look at the $207 million of total investment income in the third quarter, can you let us know how much of that was from KFN, just trying to get a sense of how that stacks up against the $53 million of net realized investment income from KFN for the quarter. And then, stepping back, how do you see that ratio holding going forward? I think, in the second quarter it was something like 2/3 of\n",
      "A1: Hi Michael, this is Bill. Thanks for the question. As it relates to KFN, you are right in that we do provide some realized information and so in the second quarter we showed in the distribution that $36 million came from KFN and in the third quarter that's $53 million, so roughly about $89 million year-to-date. On a run rate basis, that's a realized return of about 9%. When you take into account unrealized returns, which is embedded in that $207 million, KFN right now is performing much better than we had expected. That being said, KFN is a little complicated because when we closed the transaction, some of the assets were Public Market investments, CLOs, et cetera, while others were Private Market investments, which would have been Real Estate and Energy. The way we look at it is we look at this more holistically because we put all of the results from KFN and KKR proper's balance sheet together, but the bottom line is, from a modeling perspective, the realized income is on pace or a little higher than we had expected and KFN is performing rather well to date.\n",
      "Leon G. Cooperman - Omega Advisors,\n",
      "\n",
      "Q2: You guys are probably as sophisticated as any in valuing businesses. And I'm curious as to how you value your business and at what price or point would it make sense for you to take some of that, I guess, it's $11.5 billion of cash investments on your balance sheet, which is about 65% of your market cap, to basically buy back your own shares, if you thought they were misvalued or do you think they misvalued?\n",
      "A2: Thanks, Lee. Appreciate the kind comment. This is Scott. I think it's a great question. I think, today, the markets have been -- they are working to figure out how to value our business and other businesses that are somewhat like ours. In terms of how we've thought about it to date, Lee, what we've really been looking at is valuing ourselves the same way that we value companies that we invest in. We like cash flow and we look at the return on capital and the return on equity, overall. And as we've talked to our shareholders about how we think they should think about us, we have emphasized those metrics. Our perspective has been that you can't eat AUM, you can spend cash flow. And so we have been focused on making sure we're driving the total cash flow up and we took you through the numbers, you can see total distributable earnings up 75-plus percent year-to-date. So we're making progress. So far, what we've determined to do is to share that cash flow back with our investors through a high payout ratio. And year-to-date, that's been on the order of 76% of the cash flow we've paid out in the distribution, which has been also increasing rather significantly. When we looked at how to take these trade-offs views before, what we've looked at is year-to-date and over the last few years, our ROE has been 25-plus percent. And so, when we've looked at opportunities to invest capital internally versus buying shares back, we've kind of put it all in the mixer and said, \"All right, we can deploy our capital against opportunities we have and generate 25-plus percent returns on that capital,\" that's a pretty good return. So while we think our stock does not properly reflect the cash flow we generate, we found attractive ways to deploy capital internally and have been to date returning capital to shareholders through a very high payout ratio and a very high dividend. I think you're asking a good question. Is that the right approach for the long-term? And the answer is this is the approach we've taken so far, but we'll continue to look at it.\n",
      "Christoph M. Kotowski - Oppenheimer & Co. Inc.,\n",
      "\n",
      "Q3: Just 2 things. One is the -- in the Public Markets, the unrealized investment losses, the $46 million that we see, is that primarily the mark-to-market on the CLOs and KFN, because you could see that they were marked prior -- slightly above cost in the second quarter and slightly below in the third?\n",
      "A3: That's absolutely right, Chris.\n",
      "Christoph M. Kotowski - Oppenheimer & Co. Inc.,\n",
      "\n",
      "Q4: Okay. And then just a kind of bigger picture. In the recent weeks, there were 3 kind of un-KKR like investments, smaller, more ventured capital kind of investments, Magic Leap, Lemon Restaurants, Ping Identity and things that I don't think have been down the center of the fairway for KKR. And can you discuss that strategy and where they fit in the grand scheme of things?\n",
      "A4: Yes, Chris, happy to. This is Scott. Look, I think, we have found across a number of the different industries that we spend time in, Chris, that periodically we've run across interesting smaller investment opportunities that are more growth equity in nature. Historically, we have passed on those because it didn't fit into a private equity mandate or any of the other strategies that we manage, but we've found many of them to be quite interesting. And so there are some sectors. Technology, retail, healthcare have been those most active. We're now with our balance sheet, we've taken the view that we can actually make some of those investments, which we're doing on balance sheet today. We'll see how this strategy evolves. As you recall, with our Real Estate strategy, that started as an on-balance sheet strategy that we dropped into a fund. We may do that with growth equity down the line and we may not, but think of these as opportunities sourced by our investment teams that historically we passed on and now we have a way to monetize.\n",
      "M. Patrick Davitt -\n",
      "\n",
      "Q5: You talked a lot about the growth in your strategies that are moving into their second generation of funds. Can you give us an update on where each of those stand in terms of either raising that second generation or starting to raise that second generation?\n",
      "A5: Sure, Patrick. So let me just run through a number of different strategies because this also feeds well into kind of what we're doing from a fundraising standpoint in the market. But if you kind of go around the world and across the different businesses, as you know, we recently raised our Asia II Fund for private equity. So that was our private equity successor fund that was about $6 billion. We have a number of Fund II strategies that we're actually in market with now or will be shortly, including infrastructure, our direct lending platform, where we're raising fund to special situations, which is also in the market with Fund II mezzanine II or a private credit II, is also a strategy that we're going to be raising here shortly. So a number of different strategies that we're in the market with Fund II right now. And then, there's others that you'll see coming, including Real Estate. So as you kind of go across all the different strategies, and I think there is 7 or 8 different vehicles that we've built, where we had Fund Is. A number of those have already launched Fund II and more are coming.\n",
      "Marc S. Irizarry - Goldman Sachs Group Inc.,\n",
      "\n",
      "Q6: Scott, can you just address the environment in terms of what you might expect from strategic versus ECM exit outlook? I'm particularly curious how the recent volatility might play into maybe the mix of exits there?\n",
      "A6: Great, happy to, Marc. Look, I think, if you look year-to-date, it's interesting. We've talked about this a lot over the course of last couple of years, that we've been seeing more and more of our exit activity, actually come from strategic exits or dividend recaps, et cetera. And if you look at what's happened year-to-date -- if you look at what's actually closed, secondaries have been about 40% of the cash that we've returned, with strategic and dividend recaps making up the other 60% or so. But if you actually kind of pro forma for a bunch of the strategic sales that we've had, remember, we've had 8 or so strategic sales announced over the course of this year. If you go back to Oriental Breweries, Sunrise, Avincis, Alliance Boots to Walgreens, Biomet, U.S. Food, Wild, Versatel. We've had a lot of strategic sales announced this year and if -- you've got 5 strategic exits, couple of which are now closed, but 3 of which are still pending. If you kind of pro forma the value that we've returned to investors, as a result of all of that, you see about 80% of that is strategic sales or dividend recaps, and only 20% or so is actually from the equity capital markets. So we have a lot of optionality as to how we exit investments and are not dependent on the Public Markets per se. So what's been pleasing for us as we thought the strategic buyers would come back and we are starting to see that come through. And as I said, it's now that and the leverage credit markets are 80-plus percent of what we're returning. So it's moving in the direction we've anticipated.\n",
      "Brian Bedell - Deutsche Bank AG,\n",
      "\n",
      "Q7: Scott, I appreciate the forward comments on the deployment opportunities. Maybe if you could just go into a little bit more detail, obviously, seeing a little bit of a rebound in the markets here, but if you could talk a little bit about how aggressive you think you might be on deploying capital and then elaborate over the next, say, 1 to 2 quarters and then in 2015. And then also a little bit more detail on the -- on some of the energy opportunities that you touched on.\n",
      "A7: Sure. Happy to, Brian. Look, I'd say, in terms of deployment, I think, it's important to keep in mind, we're a very global business, okay? So probably half -- over half of our investment teams are outside the United States and as I mentioned, we've actually been very active, in particular, over the course of last couple of quarters in Asia and Europe. And as valuations we felt were a bit high in the U.S, we pulled back a bit, especially in private equity in the U.S. But in terms of what we're seeing right now, I'd say -- let me start with Asia, active. We deployed year-to-date nearly $2 billion in private equity. We've done our second deal in Japan this year. And so we're starting to see that market open up a bit. We bought a stake in a public company in China called Haier. It's somewhere between 3 and 4x EBITDA, as that market was dislocating a little bit, so we were able to take advantage of that. But also if you look across Asia, we've been busy in special situations. And in Real Estate, and -- so we're finding a lot of different opportunities in Asia and are particularly upbeat about the special situations and kind of a rescue opportunity in that market. So I'd say, let's start there. I'd say -- I'd expect us to be quite active on the deployment front as those Capital Markets continue to develop and it's both kind of special assist, direct lending and the other areas that I mentioned. Then I'd go to Europe, the liquid markets had really started to run a bit in Europe. We've seen a bit of a pullback. We did our first deal in Africa this year, so our MENA [ph] strategy is continuing to develop, but we're also continuing to see opportunities in private credit. Special situations, direct lending, we have actually used all the capacity we have in our Real Estate Fund for European investments, so we're going to be launching a Real Estate Europe strategy as a consequence of that, and we've been expanding. We opened an office in Madrid. We're adding talent and we think direct lending type strategies are a great opportunity in Europe. So where there is dislocation, I think, you will continue to see us being very active on the deployment front. In the U.S., as I mentioned, we've been a little bit more cautious as of late, probably, more sellers than buyers in private equity, but we've continue to deploy capital in special situations, direct lending, Real Estate and Energy. So overall, where there is a little bit of fear, we get excited and find opportunity and when valuations are a bit elevated, we have a big portfolio and the opportunity to access the markets. And so, we actually are pleased with the current environment. I think we'll find things to do. In terms of your question around Energy, in particular, look, as I mentioned, we've been pretty quiet in Energy private equity for a long while because valuations had gone up so much. There's some sectors in the Energy market that have traded off in the public markets, 30% to 50%. And that will create opportunities for us, hopefully, going forward. And we're continuing to stay busy in infrastructure, energy-related and otherwise, and also in our drilling and royalty strategies, which are more private market strategies. So this is a little bit of color for you, but it's active.\n",
      "Christopher Harris - Wells Fargo Securities, LLC,\n",
      "\n",
      "Q8: So quick one on the exits. Bill, you talked about First Data, U.S. Foods and Biomet kind of in the queue. Curious if you guys expect those to close in the fourth quarter, and then if maybe you can help us out with kind of a range of potential dividends that you would expect from those exits?\n",
      "A8: Chris, this is Bill. With regard to the 3 that you mentioned, so I'll take them one by one. U.S. Food, we still haven't gotten clearance yet. We were cautiously optimistic that, that might close in the fourth quarter, but it could actually slip until the first quarter. As far as Biomet is concerned, we're hoping that's going to close in January of 2015, and so that will be a first quarter event. And lastly, on Boots, we're expecting that to take place in the first quarter of '15 as well. As far as giving any guidance on what the cash distribution would be, it's a little complicated and we'd much rather not give that type of guidance because each one of those transactions is part cash and part stock.\n",
      "M. Patrick Davitt -\n",
      "\n",
      "Q9: I just want to follow-up on my question about the CLO marks. Just -- some of the pushback I get on the story is around perceived credit risk from taking on the KFN portfolio. Just wanted to make sure that, the marks that are occurring are purely market driven and there isn't any sort of credit deterioration going on in this portfolio.\n",
      "A9: Yes. And Patrick, this is Bill. You're absolutely right. The portfolios are performing fine, but when you have disruption in a credit market on a mark-to-market basis, the CLOs might be marked down, but the underlying performance is still there and nothing that we're worried about right now. And I'd say critically, Patrick, the cash flow coming off the\n",
      "\n",
      "Q10: Which is why the results for KFN so far, both in the second quarter for the 2 months and the full third quarter, have been a little better than we actually expected.\n",
      "Christopher Harris - Wells Fargo Securities, LLC,\n",
      "A10: \n",
      "\n",
      "Q11: I guess I got back in the queue pretty quick. Scott, thanks for your comments about Energy, that's very helpful. Just had another question about an area that seems to be slowing down and that's China and Asia. Are you guys seeing any stress at all in your portfolio of companies, as a result of things slowing down there -- I mean, it appears no, but just any comments you can give us there would be great.\n",
      "A11: No. Chris, we really haven't seen a slowdown that's noticeable. In fact, our revenue and EBITDA growth in our China portfolio has been good and our overall Asia portfolio has been very good. So remember, we're focused on investing in private companies in China that have exposure to the consumer and so some of what you are seeing in the Public Markets has been disconnected from what we're experiencing in our private companies. So, so far so good on the overall portfolio in Asia, in particular. And we're kind of viewing the dislocation and the slowdown as a buying opportunity for us.\n",
      "Devin P. Ryan - JMP Securities LLC,\n",
      "\n",
      "Q12: Appreciate the color on the capital deployment. Just a follow-up, I guess, on that topic. Maybe more on the private side, but clearly, you guys want to put money to work when there is dislocations in the markets, but it hasn't been your experience that in volatile times it becomes harder to actually to get money deployed or to lock down terms just when prices have significant fluctuations? Just curious if -- clearly, you want to get the money into the market, but does it actually become harder to do when the markets are volatile?\n",
      "A12: That's a great question, Devin. So the answer is it depends on how much volatility there is and it depends on the asset class. So if it is extremely volatile and a lot of distress, then private equity, the buys are very attractive when you can make them, but only a few transactions happen if there is extreme distress, because you don't sell unless you absolutely have to, and there's not a lot of those opportunities out there. But where you've got, what we've seen so far, which is this kind of asynchronous recovery, where you've got bumps in the road from time to time, we have actually continued to see deal flow in that environment because it's not such a severe dislocation. So this has been the kind of dislocation where we're continuing to find opportunities as opposed to the market shutting down. But when you go to the other end of the spectrum, you go to our liquid businesses, market dislocation is a very attractive buying opportunity as long as the markets remain somewhat liquid, when their price deterioration and a lot of participants in those markets have short-term capital and we have long-term capital. And in the case of the balance sheet in some of the vehicles that we manage, we actually have permanent capital. So we can take advantage of those dislocations on the liquid side, and that's actually a market where we find that we can make some great buys, if the high-yield market, as an example, pulls back and becomes more attractive. And then, you've got strategies that are in between. Think private credits, special situations, mezzanine, where if companies cannot access capital because of dislocation or a change in behavior from traditional lending institutions, that's a great environment for us. So that's why this environment we've seen over the last few years of overlying kind of improving economic fundamentals, but these periodic periods of volatility are allowing us to be active across a number of our strategies and deploying capital into what we think are some pretty interesting risk/reward opportunities.\n",
      "Leon G. Cooperman - Omega Advisors,\n",
      "\n",
      "Q13: I don't know if this is an appropriate question, but you guys put a significant amount of additional capital into First Data, and\n",
      "A13: \n",
      "\n",
      "Q14: Lee, it's Scott. I think, what we'll probably do on that one, Lee, is leave it to the First Data management to talk about on their earnings call. But you're right, we did deploy significant incremental capital into that company as our largest investment, and I think it's fairly straightforward from our standpoint, we're big believers in the management team and the strategy and we wanted to have more exposure. But we'll leave it to them to give you an update on how the business is doing.\n",
      "Michael Carrier - BofA Merrill Lynch,\n",
      "A14: \n",
      "\n",
      "Q15: Scott, maybe just on some of the investments that are going into Europe. When you think about sort of the backdrop there and who knows how it plays out, but if the growth is on the slower side, how do you guys think about what you want to pay in terms of the valuation currently, when you're modeling the outlook, what the economic growth assumptions are? And then if it does slow, what can the portfolio companies do to offset it, meaning there are more on the cost side, are there revenue synergies? How do you guys think about that, because there is somewhat of a level of uncertainty in the region?\n",
      "A15: Look, I think it's a great question. But we have -- we started with the perspective that Europe is not a monolith, right? So you've got a variety of different views depending on the market. So we're finding the peripheries doing a bit better, Ireland and the U.K. are doing well; France, Netherlands, Italy, slightly better than they were, but still weak; Germany pulling back a bit. So you look at the underlying fundamentals of that company and the markets that they're exposed to. And then what we've done is we've created in the middle of the firm, a global macro and asset allocation group that's working with the teams, so we have a view on how each of those underlining economies may perform over the course of our investment horizon. And then, we layer onto that, that we have very long-dated capital. And so we're fortunate that we are in the long-dated option business so that we can create the option when we want and we can choose to exercise the option when we think it's appropriate. So we'll have a view as to when the markets may recover, but we have several years for that to happen. So it's really the way we look at it is to say what is the right way to capitalize this enterprise once we have a view as to that growth profile, given that underlying backdrop? And what we're doing is we're capitalizing these companies conservatively from debt -- capital structure standpoint and really making sure that we've got leverage to pull, operationally. The best run companies with the best management team in the industry and the highest margins, the returns probably aren't going to be there. So you need to have operational skills to actually invest in companies that you can make better. And so you kind of mix all that together and develop a model as to what you think can happen over the long term, and then we've got to make sure, even after you do all that, that we're compensated appropriately from a reward standpoint for the risk we're taking. And that analysis we do for private equity, but we also do it across our special situations platform, where we're creating some equity upside and a lot of the investments we're making, and even in direct lending type strategies, where we are more in the secure part of the capital structure, you have to think about the downside. And so -- I mean, that gives you bit of a sense for how we approach it, but it's very much market-based grounds up. Thanks, again, Stephanie. And thank you, everyone, for your interest. Happy to follow-up directly with any other questions that you might have. Thanks again.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# def create_qna_pairs(transcript, executives, analysts):\n",
    "#     \"\"\"\n",
    "#     Returns a list of dictionaries:\n",
    "#       [\n",
    "#         {\n",
    "#           \"question\": \"analyst question text here\",\n",
    "#           \"answer\": \"all combined executive responses until next question\"\n",
    "#         },\n",
    "#         ...\n",
    "#       ]\n",
    "#     Ignores 'Operator:' lines if you run remove_operator_lines() on the transcript first.\n",
    "#     \"\"\"\n",
    "#     # Split the transcript by speaker\n",
    "#     sections = re.split(r\"(?<!\\w)([A-Z][a-zA-Z\\s.']+):\", transcript)\n",
    "\n",
    "#     qna_list = []\n",
    "#     current_question = None\n",
    "#     current_answers = []    \n",
    "\n",
    "#     if len(sections) < 3:\n",
    "#         return qna_list  # No valid speaker-dialogue chunks\n",
    "\n",
    "#     # Walk through the transcript in speaker-dialogue pairs\n",
    "#     for i in range(1, len(sections) - 1, 2):\n",
    "#         speaker = sections[i].strip()\n",
    "#         dialogue = sections[i+1].strip()\n",
    "\n",
    "#         # Check if the speaker is an analyst => new question\n",
    "#         if any(token in analysts for token in speaker.split()):\n",
    "#             # If there's an existing question, finalize its Q&A pair\n",
    "#             if current_question is not None:\n",
    "#                 # Join all answer snippets into one\n",
    "#                 qna_list.append({\n",
    "#                     \"question\": current_question,\n",
    "#                     \"answer\": \" \".join(current_answers)\n",
    "#                 })\n",
    "            \n",
    "#             # Start a new question\n",
    "#             current_question = dialogue\n",
    "#             current_answers = []\n",
    "        \n",
    "#         # If the speaker is an executive => part of the answer\n",
    "#         elif any(token in executives for token in speaker.split()):\n",
    "#             if current_question is not None:\n",
    "#                 current_answers.append(dialogue)\n",
    "#             else:\n",
    "#                 # There's an executive speaking before any question - optional handling\n",
    "#                 pass\n",
    "#         else:\n",
    "#             # Speaker is neither analyst nor executive (maybe Operator or something else).\n",
    "#             # Typically we ignore them unless you want to handle them specially.\n",
    "#             pass\n",
    "\n",
    "#     # After the loop, if there's a question in progress, finalize it\n",
    "#     if current_question is not None:\n",
    "#         qna_list.append({\n",
    "#             \"question\": current_question,\n",
    "#             \"answer\": \" \".join(current_answers)\n",
    "#         })\n",
    "\n",
    "#     return qna_list\n",
    "\n",
    "# cleaned_transcript = remove_operator_lines(after_second_operator)\n",
    "\n",
    "# # 2) Build Q&A pairs\n",
    "# qna_results = create_qna_pairs(cleaned_transcript, executives, analysts)\n",
    "\n",
    "# # 3) Print them\n",
    "# for i, item in enumerate(qna_results, start=1):\n",
    "#     print(f\"Q{i}: {item['question']}\")\n",
    "#     print(f\"A{i}: {item['answer']}\")\n",
    "#     print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "8dc904b3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[]\n"
     ]
    }
   ],
   "source": [
    "# def get_question_response_pairs(transcript, executives, analysts):\n",
    "#     # Remove all sections where the speaker is \"Operator:\"\n",
    "#     transcript_without_operator = re.sub(r\"Operator:.*?(?=\\n[A-Z][a-zA-Z\\s.']+:|$)\", \"\", transcript, flags=re.DOTALL)\n",
    "\n",
    "#     # Split the cleaned transcript into individual speaker sections using regex\n",
    "#     sections = re.split(r\"\\n([A-Z][a-zA-Z\\s.']+):\", transcript_without_operator)\n",
    "\n",
    "#     # Ensure valid splitting\n",
    "#     if len(sections) < 3:\n",
    "#         return []  # Return an empty list if no valid sections are found\n",
    "\n",
    "#     # Initialize variables\n",
    "#     question_response_pairs = []\n",
    "#     current_question = None\n",
    "#     current_responses = []\n",
    "\n",
    "#     # Iterate through sections to identify speakers and their dialogues\n",
    "#     for i in range(1, len(sections) - 1, 2):  # Step by 2 (speakers and dialogues are paired)\n",
    "#         speaker = sections[i].strip()\n",
    "#         dialogue = sections[i + 1].strip()\n",
    "\n",
    "#         # Check if the speaker is in the analysts list (indicating a question)\n",
    "#         if any(name in analysts for name in speaker.split()):\n",
    "#             # If there is a current question, store the pair\n",
    "#             if current_question:\n",
    "#                 question_response_pairs.append({\"question\": current_question, \"response\": \" \".join(current_responses)})\n",
    "#             # Start a new question\n",
    "#             current_question = dialogue\n",
    "#             current_responses = []\n",
    "#         # Check if the speaker is in the executives list (indicating a response)\n",
    "#         elif any(name in executives for name in speaker.split()):\n",
    "#             current_responses.append(dialogue)\n",
    "\n",
    "#     # Add the last question-response pair (if any)\n",
    "#     if current_question:\n",
    "#         question_response_pairs.append({\"question\": current_question, \"response\": \" \".join(current_responses)})\n",
    "\n",
    "#     return question_response_pairs\n",
    "\n",
    "\n",
    "\n",
    "# question_response_pairs = get_question_response_pairs(after_second_operator, executives, analysts)\n",
    "\n",
    "# print(question_response_pairs)\n",
    "\n",
    "# # Print results\n",
    "# for i, pair in enumerate(question_response_pairs, start=1):\n",
    "#     print(f\"Q{i}: {pair['question']}\")\n",
    "#     print(f\"A{i}: {pair['response']}\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "29b74620",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[]\n"
     ]
    }
   ],
   "source": [
    "# print(responses)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "c1229571",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Michael S. Kim - Sandler O'Neill + Partners, L.P., Research Division Leon G. Cooperman - Omega Advisors, Inc. Christoph M. Kotowski - Oppenheimer & Co. Inc., Research Division M. Patrick Davitt - Autonomous Research LLP Marc S. Irizarry - Goldman Sachs Group Inc., Research Division Brian Bedell - Deutsche Bank AG, Research Division Christopher Harris - Wells Fargo Securities, LLC, Research Division Devin P. Ryan - JMP Securities LLC, Research Division Michael Carrier - BofA Merrill Lynch, Research Division\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# analysts_section = re.search(r\"Analysts:(.*?)Operator:\", transcript2, re.DOTALL).group(1)\n",
    "\n",
    "\n",
    "# # Extract names from the section\n",
    "# # names = re.findall(r\"[A-Z][a-zA-Z]+\\s[A-Z][a-zA-Z]+\", analysts_section)\n",
    "\n",
    "# # Print the result\n",
    "# print(analysts_section)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
